Compounds > er-086526
Page last updated: 2024-11-12

er-086526

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

eribulin: a halichondrin B derivative that suppresses microtubule growth and acts as an antimitotic agent; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

eribulin : A fully synthetic macrocyclic ketone analogue of marine sponge natural products. Inhibits growth phase of microtubules via tubulin-based antimitotic mechanism, which leads to G2/M cell-cycle block, disruption of mitotic spindles, and, ultimately, apoptotic cell death after prolonged mitotic blockage [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID11354606
CHEMBL ID1683590
CHEBI ID63587
SCHEMBL ID15783821
MeSH IDM0493225

Synonyms (40)

Synonym
er-086526
nsc-707389
b 1939
eribulin [inn]
unii-lr24g6354g
lr24g6354g ,
er 086526
(1s,3s,6s,9s,12s,14r,16r,18s,20r,21r,22s,26r,29s,31r,32s,35r,36s)-20-[(2s)-3-amino-2-hydroxypropyl]-21-methoxy-14-methyl-8,15-bis(methylene)-2,19,30,34,37,39,40,41-octaoxanonacyclo[24.9.2.1(3,32).1(3,33).1(6,9).1(12,16).0(18,22).0(29,36).0(31,35)]hentetra
CHEBI:63587 ,
2-(3-amino-2-hydroxypropyl)hexacosahydro-3-methoxy-26-methyl-20,27-bis(methylene)11,15-18,21-24,28-triepoxy-7,9-ethano-12,15-methano-9h,15h-furo(3,2-i)furo(2',3'-5,6)pyrano(4,3-b)(1,4)dioxacyclopentacosin-5-(4h)-one
eribulin
253128-41-5
gtpl6813
CHEMBL1683590
eribulin [who-dd]
eribulin [vandf]
eribulin [mart.]
eribulin [mi]
DB08871
HY-13442
SCHEMBL15783821
(1s,3s,6s,9s,12s,14r,16r,18s,20r,21r,22s,26r,29s,31r,32s,33r,35r,36s)-20-[(2s)-3-amino-2-hydroxypropyl]-21-methoxy-14-methyl-8,15-dimethylidene-2,19,30,34,37,39,40,41-octaoxanonacyclo[24.9.2.1~3,32~.1~3,33~.1~6,9~.1~12,16~.0~18,22~.0~29,36~.0~31,35~]hente
UFNVPOGXISZXJD-JBQZKEIOSA-N
(1s,3s,6s,9s,12s,14r,16r,18s,20r,21r,22s,26r,29s,31r,32s,33r,35r,36s)-20-[(2s)-3-amino-2-hydroxypropyl]-21-methoxy-14-methyl-8,15-dimethylidene-2,19,30,34,37,39,40,41-octaoxanonacyclo[24.9.2.13,32.13,33.16,9.112,16.018,22.029,36.031,35]hentetracontan-24-o
e7389-lf
Q408717
NCGC00510497-02
AT36513
MS-31267
DTXSID101009321 ,
(1s,3s,6s,9s,12s,14r,16r,18s,20r,21r,22s,26r,29s,31r,32s,35r,36s)-20-((2s)-3-amino-2-hydroxypropyl)-21-methoxy-14-methyl-8,15-bis(methylene)-2,19,30,34,37,39,40,41-octaoxanonacyclo(24.9.2.1(3,32).1(3,33).1(6,9).1(12,16).0(18,22).0(29,36).0(31,35))hentetra
l01xx41
eribuline
eribulin (mart.)
eribulinum
dtxcid701436148
eribulina
EX-A4873D
BP-29357
AKOS040740784

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" The adverse effect profile of eribulin in this trial was similar to that of taxanes; neutropenia and peripheral neuropathy were the most frequent adverse effects."( Eribulin: Heavily pretreated breast cancer: uncertain advantages, excessive adverse effects.
, 2012)		0.38
" The most frequent adverse events observed in patients receiving eribulin were asthenia/fatigue, neutropenia, alopecia, peripheral neuropathy and nausea."( Effectiveness and safety of eribulin mesylate: a new therapeutic option in the treatment of metastatic breast cancer.
Kelly, CM; O'Sullivan Coyne, G; Walsh, J, 2012)		0.38
" The proportion reporting at least one adverse event (any grade) with C, G, V, and E was 45%, 65%, 75%, and 63%."( A comparison of toxicity and health care resource use between eribulin, capecitabine, gemcitabine, and vinorelbine in patients with metastatic breast cancer treated in a community oncology setting.
Beegle, N; Blau, S; Cox, D; Dranitsaris, G; Faria, C; Kalberer, T, 2015)		0.42
" In terms of adverse events(AEs), observed cases of hematotoxicity were of neutropenia(75%), leucopenia(75%), and anemia(80%)."( [Efficacy and safety of eribulin for metastatic breast cancer patients].
Egawa, C; Hamanaka, M; Hashimoto, N; Kato, T; Kawashima, H; Kusama, H; Matsushita, K; Mukai, Y; Nakahira, S; Okishiro, M; Sakisaka, H; Suzuki, R; Takatsuka, Y; Takeda, Y; Takeno, A; Tamura, S; Taniguchi, H, 2014)		0.4
" No hypersensitivity reactions and no toxic deaths were seen."( A retrospective safety and efficacy analysis of the first patients treated with eribulin for metastatic breast cancer in Stockholm, Sweden.
Bergh, J; Falato, C; Foukakis, T; Kessler, L; Margolin, S, 2015)		0.42
"Eribulin administered outside of a clinical trial in patients with advanced breast cancer was safe and well tolerated."( A retrospective safety and efficacy analysis of the first patients treated with eribulin for metastatic breast cancer in Stockholm, Sweden.
Bergh, J; Falato, C; Foukakis, T; Kessler, L; Margolin, S, 2015)		0.42
" Most common grade 3-4 adverse events (AEs) were neutropenia (38%), asthenia (10%) and peripheral neuropathy (7%)."( [Efficacy, safety and cost of eribulin in patients with metastatic breast cancer].
Bazan, F; Chaigneau, L; Curtit, E; Dobi, E; Mansi, L; Meneveau, N; Montcuquet, P; Nerich, V; Paillard, MJ; Pivot, X; Thiery-Vuillemin, A; Villanueva, C, 2015)		0.42
" Dose delays, reductions, and interruptions due to treatment-emergent adverse events occurred in 35."( Safety and tolerability of eribulin mesylate in patients with pretreated metastatic breast cancer.
Barbour, S; Berrak, E; Cox, D; Goodin, S; Song, J, 2015)		0.42
"The most frequent grade 3 hematologic adverse events were neutropenia (56%) and anemia (20%)."( Safety of eribulin mesylate and concomitant radiotherapy for metastatic breast cancer: a single-center experience.
Agresti, B; Baldazzi, V; Bernini, M; Bianchi, S; Casella, D; De Luca Cardillo, C; Desideri, I; Detti, B; Di Cataldo, V; Fambrini, M; Francolini, G; Greto, D; Livi, L; Loi, M; Mangoni, M; Meattini, I; Nori, J; Orzalesi, L; Sanchez, LJ; Scotti, V, 2016)		0.43
" No hypersensitivity reactions and no toxic deaths were observed."( Efficacy and safety of eribulin monotherapy in patients with heavily pretreated metastatic breast cancer.
Akin, S; Aksoy, S; Altundag, K; Ates, O; Babacan, T; Cenoli, A; Karakas, Y; Kertmen, N; Kilickap, S; Ozisik, Y; Sarici, F; Sever, AR, )		0.13
"Eribulin monotherapy is an effective and safe regimen for MBC patients."( Efficacy and safety of eribulin monotherapy in patients with heavily pretreated metastatic breast cancer.
Akin, S; Aksoy, S; Altundag, K; Ates, O; Babacan, T; Cenoli, A; Karakas, Y; Kertmen, N; Kilickap, S; Ozisik, Y; Sarici, F; Sever, AR, )		0.13
"6% of adverse eventsBGrade 3; however, the recovery was rapid."( [Treatment Continuation and Safety of Eribulin for the Treatment of Metastatic Breast Cancer].
Adachi, S; Asano, H; Ito, D; Iwai, M; Kamei, K; Okada, K; Usami, E; Yoshimura, T, 2016)		0.43
" The common grade 3/4 adverse events were neutropenia (25 patients; 53."( Efficacy and safety of eribulin as first- to third-line treatment in patients with advanced or metastatic breast cancer previously treated with anthracyclines and taxanes.
Kai, Y; Kurashita, K; Maeda, S; Mashino, K; Minami, S; Mitsuyama, S; Nishimura, R; Saimura, M; Shimokawa, M; Tamura, K; Yano, H, 2017)		0.46
" The most experienced adverse event was asthenia/fatigue (58%), followed by neutropenia (30%)."( Efficacy and safety of eribulin in taxane-refractory patients in the 'real world'.
Barni, S; Cinieri, S; Del Mastro, L; Latorre, A; Lorusso, V; Porcu, L; Puglisi, F, 2017)		0.46
" The most common adverse event was neutropenia, which occurred in 57% of eribulin patients and 49% of TPC patients at all grades."( A randomized, open-label, multicenter, phase 3 study to compare the efficacy and safety of eribulin to treatment of physician's choice in patients with advanced non-small cell lung cancer.
Barlesi, F; Felip, E; Guo, M; Iannotti, N; Katakami, N; Kim, JH; Nokihara, H; Olivo, M; Satouchi, M; Spigel, DR; Yang, JC, 2017)		0.46
" We compared the relative dose intensity (RDI), tumor response, progression-free survival (PFS), overall survival (OS), and adverse events between the groups."( Efficacy and safety of eribulin in patients with locally advanced or metastatic breast cancer not meeting trial eligibility criteria: a retrospective study.
Bun, S; Fujiwara, Y; Iizumi, S; Kodaira, M; Noguchi, E; Shimizu, C; Shimoi, T; Shimomura, A; Tamura, K; Tsushita, N; Yonemori, K; Yunokawa, M, 2017)		0.46
" Initial dose reduction and treatment discontinuation due to adverse events (AEs) were more common in the ineligible group (initial dose reduction: 23."( Efficacy and safety of eribulin in patients with locally advanced or metastatic breast cancer not meeting trial eligibility criteria: a retrospective study.
Bun, S; Fujiwara, Y; Iizumi, S; Kodaira, M; Noguchi, E; Shimizu, C; Shimoi, T; Shimomura, A; Tamura, K; Tsushita, N; Yonemori, K; Yunokawa, M, 2017)		0.46
"6%) experienced an adverse event (AE) related to treatment including 129 (51."( Safety Results and Analysis of Eribulin Efficacy according to Previous Microtubules-Inhibitors Sensitivity in the French Prospective Expanded Access Program for Heavily Pre-treated Metastatic Breast Cancer.
Bertucci, F; Brain, E; Diéras, V; Extra, JM; Gonçalves, A; Monneur, A; Pivot, X; Provansal, M; Roché, H; Sabatier, R; Tarpin, C; Viens, P; Zemmour, C, 2018)		0.48
" Common grade 3/4 adverse events were neutropenia (42."( A phase II, multicenter, single-arm trial of eribulin as first- or second-line chemotherapy for HER2-negative advanced or metastatic breast cancer: evaluation of efficacy, safety, and patient-reported outcomes.
Fujioka, H; Iwamoto, M; Kawaguchi, K; Kimura, K; Matsunami, N; Morimoto, T; Nitta, T; Ogura, H; Takahashi, Y; Tanaka, S; Terasawa, R; Uchiyama, K; Yamamoto, D; Yoshidome, K, 2018)		0.48
"Chemotherapy-induced peripheral neuropathy (CIPN) is a severe and common side effect induced by a variety of anticancer drugs."( [Peripheral neuropathy as a side effect of chemotherapy and targeted therapy].
Gießen-Jung, C; von Baumgarten, L, 2018)		0.48
"Eribulin is active and safe in heavily pre-treated metastatic breast cancer patients."( Safety of eribulin as third-line chemotherapy in HER2-negative, advanced breast cancer pre-treated with taxanes and anthracycline: OnSITE study.
Ballesteros García, A; Borrega García, P; Chacón López-Muñíz, I; Ciruelos Gil, E; Delgado Mingorance, JI; Echarri González, MJ; García-Sáenz, JA; Izarzugaza Perón, Y; López-González, A; Manso, L; Martínez-Jañez, N; Moreno Antón, F; Olier Garate, C; Paz-Ares, L, 2019)		0.51
"Pneumothorax has been reported as a pazopanib-associated adverse event in patients with lung metastases of soft tissue sarcoma (STS)."( Pneumothorax as an Adverse Event in Patients with Lung Metastasis of Soft Tissue Sarcoma under Eribulin Treatment.
Arihara, Y; Emori, M; Hayasaka, N; Ikeda, H; Iyama, S; Kato, J; Kobune, M; Miyanishi, K; Murase, K; Nakamura, H; Nakamura, K; Sugita, S; Takada, K, 2019)		0.51
" However, soon after their introduction into clinical practice, chemotherapy-induced peripheral neurotoxicity (CIPN) emerged as their main non-hematological and among dose-limiting adverse events."( Vinca alkaloids, thalidomide and eribulin-induced peripheral neurotoxicity: From pathogenesis to treatment.
Alberti, P; Argyriou, AA; Islam, B; Kolb, N; Lustberg, M; Staff, NP, 2019)		0.51
" Neutropenia was the most common grade 3/4 clinical adverse event (16."( Eribulin plus trastuzumab in pretreated HER2-positive advanced breast cancer patients: safety and efficacy. An Italian experience.
Bilancia, D; Caliolo, C; Calvani, N; Cinieri, S; Dima, G; Febbraro, A; Fedele, P; Ferrara, P; Filippelli, G; Fontanella, C; Giampaglia, M; Giordano, G; Lutrino, ES; Marino, A; Orlando, L; Quaranta, AM; Rubino, D; Scavelli, C; Schiavone, P; Zamagni, C, 2020)		0.56
" Grade ≥ 3 adverse drug reactions (ADRs) were reported in 61."( Effectiveness and safety of eribulin in Japanese patients with HER2-negative, advanced breast cancer: a 2-year post-marketing observational study in a real-world setting.
Egawa, C; Ikezawa, H; Inoue, K; Matsuoka, T; Mukai, H; Sakata, Y; Takahashi, M; Tsurutani, J; Yamanaka, T, 2020)		0.56
"Adverse events (AE) during oncology clinical trials are typically reported using the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE), which provides information about the frequency and severity of AEs from the provider's perspective."( A dynamic portrait of adverse events for breast cancer patients: results from a phase II clinical trial of eribulin in advanced HER2-negative breast cancer.
Burstein, HJ; Come, S; Constantine, M; Faggen, M; Filho, OM; Freedman, RA; Giobbie-Hurder, A; Lin, NU; Mayer, EL; Openshaw, T; Schneider, B; Walsh, J, 2021)		0.62
" The only grade ≥3 clinical adverse events in >5% of patients were hypertension (39%), neutropenia (26%), thrombosis (10%), and paresthesia/dysesthesia (7%)."( First-line bevacizumab and eribulin combination therapy for HER2-negative metastatic breast cancer: Efficacy and safety in the GINECO phase II ESMERALDA study.
Brocard, F; Clatot, F; Despax, R; Emile, G; Ferrero, JM; Grenier, J; Hardy-Bessard, AC; Lortholary, A; Lucas, B; Marti, A; Martin-Babau, J; Meunier, J; Moullet, I; Savoye, AM; You, B, 2020)		0.56
" The most common adverse events were grade 1-2 anemia (n=12, 33%), neutropenia (n=12, 33%) and grade 3-4 neuropathy (n=4, 11."( Efficacy and safety evaluation of eribulin-trastuzumab combination therapy with heavily pretreated HER2-positive metastatic breast cancer.
Altundag, K; Sarici, F, )		0.13
"Eribulin-trastuzumab combination is an effective and safe treatment option with a low toxicity profile for aggressively pre-treated patients with metastatic breast cancer."( Efficacy and safety evaluation of eribulin-trastuzumab combination therapy with heavily pretreated HER2-positive metastatic breast cancer.
Altundag, K; Sarici, F, )		0.13
" Primary effectiveness and safety outcomes were overall survival (OS) and adverse events (AE), respectively."( Comparative effectiveness and safety of eribulin in advanced or metastatic breast cancer: a systematic review and meta-analysis.
Johnson, BS; Qian, J; Tanni, KA; Truong, CB, 2021)		0.62
" Progression- free survival（PFS）and the efficacy of eribulin, influencing factors, and adverse reactions were analysed."( Treatment Strategy and Safety of Eribulin in Advanced Breast Cancer.
Liu, S; Wang, X; Xue, Y, 2022)		0.72
" However, severe adverse effects (SAEs) occur in 30-40% of the patients, and significantly reduce the patients' quality of life and disturb the recommended treatment schedules."( Risk Factor Analysis for the Occurrence of Severe Adverse Effects in Eribulin Treatment.
Dosaka-Akita, H; Kinoshita, I; Noguchi, T; Saito, Y; Shimizu, Y; Sugawara, M; Takekuma, Y; Takeshita, T; Takeuchi, S, 2022)		0.72
" Progression-free survival (PFS), overall survival (OS), objective response rate (ORR), disease control rate (DCR), adverse effects (AEs) and health-related quality of life (HRQoL) were assessed."( Effectiveness, safety, and impact on quality of life of eribulin-based therapy in heavily pretreated patients with metastatic breast cancer: A real-world analysis.
Gui, X; Li, H; Liang, X, 2023)		0.91
" The most common grade 3-4 adverse events were neutropenia (22."( Effectiveness, safety, and impact on quality of life of eribulin-based therapy in heavily pretreated patients with metastatic breast cancer: A real-world analysis.
Gui, X; Li, H; Liang, X, 2023)		0.91

Pharmacokinetics

ExcerptReferenceRelevance
"Eribulin (E7389), a mechanistically unique microtubule inhibitor in phase III clinical trials for cancer, exhibits superior efficacy in vivo relative to the more potent compound ER-076349, a fact not explained by different pharmacokinetic properties."( Eribulin induces irreversible mitotic blockade: implications of cell-based pharmacodynamics for in vivo efficacy under intermittent dosing conditions.
Aalfs, KK; Kishi, Y; Lewis, BM; Littlefield, BA; Salvato, KA; Seletsky, BM; Towle, MJ; Wels, BF; Yu, MJ; Zheng, W; Zhu, X, 2011)		0.37
" Pharmacokinetic sampling for determination of eribulin plasma concentration was performed up to 144 h following administration of eribulin mesylate."( Eribulin mesylate pharmacokinetics in patients with solid tumors receiving repeated oral ketoconazole.
Beijnen, JH; Copalu, W; Devriese, LA; Edwards, G; Jenner, A; Marchetti, S; Mergui-Roelvink, M; Peng, F; Reyderman, L; Schellens, JH; Wanders, J, 2013)		0.39
" Pharmacokinetic sampling for determination of eribulin plasma concentrations was performed up to 144 h following administration."( Pharmacokinetics of eribulin mesylate in patients with solid tumours receiving repeated oral rifampicin.
Beijnen, JH; Copalu, W; Devriese, LA; Edwards, G; Huitema, AD; Law, K; Marchetti, S; Peng, F; Reyderman, L; Schellens, JH; Voest, EE; Wanders, J; Witteveen, PE, 2013)		0.39
"Fourteen patients were included and 11 patients were evaluable for pharmacokinetic analysis."( Pharmacokinetics of eribulin mesylate in patients with solid tumours receiving repeated oral rifampicin.
Beijnen, JH; Copalu, W; Devriese, LA; Edwards, G; Huitema, AD; Law, K; Marchetti, S; Peng, F; Reyderman, L; Schellens, JH; Voest, EE; Wanders, J; Witteveen, PE, 2013)		0.39
"A phase I, pharmacokinetic study was performed in patients with advanced solid tumors and normal hepatic function or Child-Pugh A (mild) or Child-Pugh B (moderate) hepatic impairment."( Pharmacokinetics of eribulin mesylate in patients with solid tumors and hepatic impairment.
Beijnen, JH; Devriese, LA; Edwards, G; Jenner, A; Marchetti, S; Mergui-Roelvink, M; Reyderman, L; Schellens, JH; Voest, EE; Wanders, J; Witteveen, PO, 2012)		0.38
" The relationship between eribulin pharmacokinetic and neutropenia was described using a semi-physiological lifespan model for haematological toxicity."( Population pharmacokinetic-pharmacodynamic analysis for eribulin mesilate-associated neutropenia.
Beijnen, JH; Gupta, A; Huitema, AD; Hussein, Z; Schellens, JH; van Hasselt, JG, 2013)		0.39
" To investigate its resistance mechanisms, we developed a fluorescent analog of eribulin with pharmacokinetic (PK) properties and cytotoxic activity across a human cell line panel that are sufficiently similar to the parent drug to study its cellular PK and tissue distribution."( Single-cell pharmacokinetic imaging reveals a therapeutic strategy to overcome drug resistance to the microtubule inhibitor eribulin.
Kim, E; Kohler, RH; Laughney, AM; Miller, MA; Mitchison, TJ; Orth, JD; Sprachman, MM; Weissleder, R; Yang, KS, 2014)		0.4
" Changes in neutrophil counts over time were analyzed using a mechanistic pharmacodynamic model."( Pharmacodynamic analysis of eribulin safety in breast cancer patients using real-world postmarketing surveillance data.
Fermanelli, V; Ishii, M; Kasai, H; Kawamura, T; Matsuoka, T; Sakata, Y; Takahashi, T; Tanigawara, Y, 2018)		0.48
" In conclusion, a robust method for released and total eribulin levels in dog plasma was developed and was successfully applied to a pharmacokinetic study in dogs to characterize the pharmacokinetic profiles."( A separate assay of released and liposomal encapsulated eribulin in dog plasma by liquid chromatography with tandem mass spectrometry for its application to a pharmacokinetic study.
Mano, Y, 2022)		0.72

Compound-Compound Interactions

ExcerptReferenceRelevance
" This phase I study aimed to determine the maximum tolerated dose (MTD), dose-limiting toxicities (DLTs), and pharmacokinetics in combination with cisplatin (CP) in patients with advanced solid tumours."( Phase I study of the halichondrin B analogue eribulin mesylate in combination with cisplatin in advanced solid tumors.
Carroll, MI; Chung, VM; Cristea, MC; Doyle, LA; El-Khoueiry, AB; Frankel, PH; Gandara, DR; Koczywas, M; Lau, DH; Lenz, HJ; Lim, D; Mortimer, JE; Newman, EM; Reckamp, KL; Ruel, C; Synold, TW, 2014)		0.4
" Eribulin mesylate was administered on days 1, 8, and 15 in combination with CP day 1 every 28-day cycle."( Phase I study of the halichondrin B analogue eribulin mesylate in combination with cisplatin in advanced solid tumors.
Carroll, MI; Chung, VM; Cristea, MC; Doyle, LA; El-Khoueiry, AB; Frankel, PH; Gandara, DR; Koczywas, M; Lau, DH; Lenz, HJ; Lim, D; Mortimer, JE; Newman, EM; Reckamp, KL; Ruel, C; Synold, TW, 2014)		0.4
"2 mg m(-2), administered on days 1 and 8, in combination with CP 75 mg m(-2), administered on day 1 is well tolerated and showed preliminary anticancer activity."( Phase I study of the halichondrin B analogue eribulin mesylate in combination with cisplatin in advanced solid tumors.
Carroll, MI; Chung, VM; Cristea, MC; Doyle, LA; El-Khoueiry, AB; Frankel, PH; Gandara, DR; Koczywas, M; Lau, DH; Lenz, HJ; Lim, D; Mortimer, JE; Newman, EM; Reckamp, KL; Ruel, C; Synold, TW, 2014)		0.4
" Fifteen patients were enrolled in a dose escalation of eribulin mesylate in combination with pemetrexed (E+P)."( An open-label, multicenter, randomized phase Ib/II study of eribulin mesylate administered in combination with pemetrexed versus pemetrexed alone as second-line therapy in patients with advanced nonsquamous non-small-cell lung cancer.
Bondarenko, I; Dave, H; Freeman, A; Hodge, JP; Huber, B; Lieberman, R; Shelton, MJ; Shparyk, Y; Vynnychenko, I; Waller, CF, 2015)		0.42
"4 mg/m(2) intravenously on days 1 and 8 of each cycle) combined with capecitabine (900 mg/m(2) orally twice daily on days 1-14 of each cycle [standard schedule] or 1500 mg orally twice daily using a 7-days on/7-days off schedule [weekly schedule])."( Phase II, Multicenter, Single-Arm, Feasibility Study of Eribulin Combined With Capecitabine for Adjuvant Treatment in Estrogen Receptor-Positive, Early-Stage Breast Cancer.
Berrak, E; Hoffman, AD; Jones, VE; McIntyre, K; O'Shaughnessy, J; Smith, JW; Song, JX; Vukelja, S, 2016)		0.43
"The VERITAS (A Phase 1B open-label study to assess the safety and tolerability of everolimus in combination with eribulin in triple-negative breast cancers) trial (EudraCT number: 2014-000135-17) is a phase Ib, open label, multicenter, dose-escalation, safety, pharmacokinetic, and pharmacodynamic study based on the combination of everolimus with eribulin in sequential cohorts of metastatic triple negative breast cancer (TNBC) patients."( A Phase Ib Open-Label Study to Assess the Safety and Tolerability of Everolimus in Combination With Eribulin in Triple-Negative Breast Cancers.
Bottini, A; Cappelletti, MR; Generali, D; Gobbi, A; Milani, M; Roviello, G; Senti, C; Sigala, S; Strina, C; Zanotti, L, 2016)		0.43
"The primary objective of the study is to identify the recommended dose of everolimus in combination with eribulin."( A Phase Ib Open-Label Study to Assess the Safety and Tolerability of Everolimus in Combination With Eribulin in Triple-Negative Breast Cancers.
Bottini, A; Cappelletti, MR; Generali, D; Gobbi, A; Milani, M; Roviello, G; Senti, C; Sigala, S; Strina, C; Zanotti, L, 2016)		0.43
"The VERITAS trial is expected to determine the recommended dose of everolimus in combination with eribulin in TBNC."( A Phase Ib Open-Label Study to Assess the Safety and Tolerability of Everolimus in Combination With Eribulin in Triple-Negative Breast Cancers.
Bottini, A; Cappelletti, MR; Generali, D; Gobbi, A; Milani, M; Roviello, G; Senti, C; Sigala, S; Strina, C; Zanotti, L, 2016)		0.43
" This study investigated eribulin in combination with pertuzumab and trastuzumab for both taxane- and trastuzumab-pretreated HER2-positive ABC patients."( First report of eribulin in combination with pertuzumab and trastuzumab for advanced HER2-positive breast cancer.
Akiyama, F; Araki, K; Fukada, I; Horii, R; Ito, Y; Kobayashi, K; Ohno, S; Shibayama, T; Takahashi, S; Yanagi, H, 2017)		0.46
"In a single-institute, single-arm, open-label, phase II trial, HER2-positive ABC patients who had previously received taxanes and trastuzumab were treated with eribulin in combination with pertuzumab and trastuzumab."( First report of eribulin in combination with pertuzumab and trastuzumab for advanced HER2-positive breast cancer.
Akiyama, F; Araki, K; Fukada, I; Horii, R; Ito, Y; Kobayashi, K; Ohno, S; Shibayama, T; Takahashi, S; Yanagi, H, 2017)		0.46
"Eribulin in combination with pertuzumab and trastuzumab was well tolerated in heavily pretreated patients."( First report of eribulin in combination with pertuzumab and trastuzumab for advanced HER2-positive breast cancer.
Akiyama, F; Araki, K; Fukada, I; Horii, R; Ito, Y; Kobayashi, K; Ohno, S; Shibayama, T; Takahashi, S; Yanagi, H, 2017)		0.46
" No significant increase in mean QTcF duration was observed with eribulin plus sorafenib versus eribulin alone; there were no drug-drug interactions."( Phase 1, open-label, dose-escalation study of sorafenib in combination with eribulin in patients with advanced, metastatic, or refractory solid tumors.
Eucker, J; Gomez-Roca, C; Graudenz, K; Huang, F; Lettieri, J; Marmé, F; Peña, C; Trnkova, ZJ, 2018)		0.48
" Here, eribulin in combination with mechanistically different anticancer agents was evaluated."( Broad-spectrum Preclinical Antitumor Activity of Eribulin (Halaven®): Combination with Anticancer Agents of Differing Mechanisms.
Asano, M; DE Boisferon, MH; Littlefield, BA; Matsui, J; McGonigle, S; Nomoto, K; Towle, MJ; Uenaka, T; Wu, J, 2018)		0.48
"Eribulin was combined with cytotoxic agents (capecitabine, carboplatin, cisplatin, doxorubicin, gemcitabine) or targeted agents (bevacizumab, BKM-120, E7449, erlotinib, everolimus, lenvatinib, palbociclib) in tumor xenograft models of breast cancer, melanoma, non-small cell lung cancer (NSCLC), and ovarian cancer."( Broad-spectrum Preclinical Antitumor Activity of Eribulin (Halaven®): Combination with Anticancer Agents of Differing Mechanisms.
Asano, M; DE Boisferon, MH; Littlefield, BA; Matsui, J; McGonigle, S; Nomoto, K; Towle, MJ; Uenaka, T; Wu, J, 2018)		0.48
" Therefore, this study attempted to demonstrate the in vitro anti-cancer activity of high-dose vitamin C in combination with conventional treatment in breast cancer."( Effect of High-dose Vitamin C Combined With Anti-cancer Treatment on Breast Cancer Cells.
Chae, YS; Jeong, JH; Jung, JH; Lee, DH; Lee, IH; Lee, J; Lee, SJ; Park, HY, 2019)		0.51
"This phase 1b study investigated the maximum tolerated dose (MTD; primary objective), safety, pharmacokinetics, and antitumor activity (secondary objectives) of eribulin combined with carboplatin in patients with solid tumors and, in particular, non-small cell lung cancer (NSCLC)."( A phase 1b, multicenter, open-label, dose-finding study of eribulin in combination with carboplatin in advanced solid tumors and non-small cell lung cancer.
Aisner, J; Dittrich, C; Goel, S; Jain, M; Kumar, K; Petrylak, DP; Reyderman, L; Song, J; Swami, U, 2019)		0.51
"Vincristine combined with camptothecin derivatives showed synergy in preclinical pediatric cancer models, and the combinations are effective in treatment of childhood solid tumors."( Evaluation of Eribulin Combined with Irinotecan for Treatment of Pediatric Cancer Xenografts.
Bandyopadhyay, A; Chen, Y; Erickson, SW; Houghton, PJ; Kurmashev, D; Kurmasheva, RT; Lai, Z; Phelps, DA; Robles, AJ; Smith, MA, 2020)		0.56
"Vincristine or eribulin, alone or combined with irinotecan, was studied in 12 xenograft models."( Evaluation of Eribulin Combined with Irinotecan for Treatment of Pediatric Cancer Xenografts.
Bandyopadhyay, A; Chen, Y; Erickson, SW; Houghton, PJ; Kurmashev, D; Kurmasheva, RT; Lai, Z; Phelps, DA; Robles, AJ; Smith, MA, 2020)		0.56
"Eribulin combined with irinotecan was more effective than vincristine-irinotecan in 6 of 12 models."( Evaluation of Eribulin Combined with Irinotecan for Treatment of Pediatric Cancer Xenografts.
Bandyopadhyay, A; Chen, Y; Erickson, SW; Houghton, PJ; Kurmashev, D; Kurmasheva, RT; Lai, Z; Phelps, DA; Robles, AJ; Smith, MA, 2020)		0.56
"The results of this study suggest that second-line therapy with bevacizumab in combination with eribulin has a meaningful clinical activity and may represent a potential therapeutic option for patients with HER2-negative MBC."( Eribulin in combination with bevacizumab as second-line treatment for HER2-negative metastatic breast cancer progressing after first-line therapy with paclitaxel and bevacizumab: a multicenter, phase II, single arm trial (GIM11-BERGI).
Arpino, G; Baldini, E; Bernardo, A; Bruzzese, D; De Angelis, C; De Laurentiis, M; De Placido, P; De Placido, S; De Santo, I; Del Mastro, L; Fabi, A; Forestieri, V; Gamucci, T; Giuliano, M; Lauria, R; Leo, L; Michelotti, A; Poggio, F; Russo, S, 2021)		0.62
" This is the first published case of repeat locoregional radiation therapy in combination with eribulin."( Eribulin combined with radiation therapy in a young patient re-irradiated for a new lesion of breast cancer.
Dieng, O; Kirova, YM; Laurence, V; Logerot, C, 2021)		0.62

Bioavailability

ExcerptReferenceRelevance
" The oral bioavailability of eribulin was 62."( Interactions between the chemotherapeutic agent eribulin mesylate (E7389) and P-glycoprotein in CF-1 abcb1a-deficient mice and Caco-2 cells.
DesJardins, CS; Schuck, EL; Taur, JS; Wong, YN, 2011)		0.37
" We targeted oral bioavailability and efficacy against multidrug resistant (MDR) tumors for further work."( Novel second generation analogs of eribulin. Part II: Orally available and active against resistant tumors in vivo.
Carlson, EM; Cheng, H; Condon, K; Du, H; Eckley, S; Hu, Y; Jiang, Y; Kumar, V; Lewis, BM; Littlefield, BA; Narayan, S; Saxton, P; Schuck, E; Seletsky, BM; Tendyke, K; Towle, MJ; Yu, MJ; Zhang, H; Zheng, W, 2011)		0.37

Dosage Studied

ExcerptRelevanceReference
"Eribulin demonstrated activity with manageable tolerability (including infrequent grade 3 and no grade 4 neuropathy) in heavily pretreated patients with MBC when dosed as a short IV infusion on days 1 and 8 of a 21-day cycle."( Phase II study of eribulin mesylate, a halichondrin B analog, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane.
Ashworth, S; Blum, JL; Chandrawansa, K; Chuang, E; Cole, PE; Dacosta, NA; Fabian, CJ; Fang, F; Meneses, NL; O'Shaughnessy, J; Pruitt, B; Rivera, RR; Shuster, DE; Smith, DA; Smith, J; Tan, AR; Tan-Chiu, E; Vahdat, LT; Wright, J, 2009)		0.35
" More broadly, our results suggest that compound-specific reversibility characteristics of antimitotic agents contribute to interactions between cell-based pharmacodynamics and in vivo pharmacokinetics that define antitumor efficacy under intermittent dosing conditions."( Eribulin induces irreversible mitotic blockade: implications of cell-based pharmacodynamics for in vivo efficacy under intermittent dosing conditions.
Aalfs, KK; Kishi, Y; Lewis, BM; Littlefield, BA; Salvato, KA; Seletsky, BM; Towle, MJ; Wels, BF; Yu, MJ; Zheng, W; Zhu, X, 2011)		0.37
" To assess tolerability of a second dosing schedule, a cohort of taxane-pre-treated patients received eribulin on days 1 and 8 of a 21-day cycle."( A phase II study of eribulin mesylate (E7389) in patients with advanced, previously treated non-small-cell lung cancer.
Cole, PE; Das, A; Gabrail, NY; Iannotti, NO; Neubauer, M; Savin, MA; Shuster, D; Spira, AI; Yanagihara, RH; Zang, EA, 2012)		0.38
" Here we extend those early studies by examining the effects of eribulin against a wider spectrum of human tumor xenografts in vivo, and by directly comparing the in vivo effectiveness of different dosing administration schedules."( Broad spectrum preclinical antitumor activity of eribulin (Halaven(R)): optimal effectiveness under intermittent dosing conditions.
Asano, M; Kishi, Y; Littlefield, BA; Nomoto, K; Towle, MJ; Yu, MJ, 2012)		0.38
" Administration schedule dependence was evaluated by directly comparing q1d×5, q2d×3(×3), q4d×3, and q7d×3 schedules in the MDA-MB-435 breast cancer xenograft model, using conditions of equivalent total dosing over the course of the experiment."( Broad spectrum preclinical antitumor activity of eribulin (Halaven(R)): optimal effectiveness under intermittent dosing conditions.
Asano, M; Kishi, Y; Littlefield, BA; Nomoto, K; Towle, MJ; Yu, MJ, 2012)		0.38
" In vivo antitumor responses at these dosing levels included tumor growth inhibition, stasis, and regression; several studies showing regression also yielded long-term tumor-free survivors."( Broad spectrum preclinical antitumor activity of eribulin (Halaven(R)): optimal effectiveness under intermittent dosing conditions.
Asano, M; Kishi, Y; Littlefield, BA; Nomoto, K; Towle, MJ; Yu, MJ, 2012)		0.38
"The current results show that eribulin has broad spectrum preclinical antitumor activity against a wide variety of human cancer types, and indicate that maximum effectiveness and optimal tolerability are obtained using moderately intermittent dosing schedules."( Broad spectrum preclinical antitumor activity of eribulin (Halaven(R)): optimal effectiveness under intermittent dosing conditions.
Asano, M; Kishi, Y; Littlefield, BA; Nomoto, K; Towle, MJ; Yu, MJ, 2012)		0.38
" The pharmacokinetics of the free E7389 after dosing either E7389 or E7389-LF was characterized."( Characterization of the pharmacokinetics of a liposomal formulation of eribulin mesylate (E7389) in mice.
Desjardins, C; Lai, G; Saxton, P; Schuck, E; Wong, YN; Yu, Y, 2013)		0.39
"001) versus vehicle when measured 24 h or 2 weeks after dosing cessation, respectively."( Neuropathy-inducing effects of eribulin mesylate versus paclitaxel in mice with preexisting neuropathy.
Farah, MH; Littlefield, BA; Nomoto, K; Slusher, BS; Wozniak, KM; Wu, Y, 2013)		0.39
"During phase Ib, E+P was tolerated only at a markedly lower dosing intensity relative to the eribulin monotherapy regimen approved for breast cancer and used in phase II studies of NSCLC."( An open-label, multicenter, randomized phase Ib/II study of eribulin mesylate administered in combination with pemetrexed versus pemetrexed alone as second-line therapy in patients with advanced nonsquamous non-small-cell lung cancer.
Bondarenko, I; Dave, H; Freeman, A; Hodge, JP; Huber, B; Lieberman, R; Shelton, MJ; Shparyk, Y; Vynnychenko, I; Waller, CF, 2015)		0.42
" Hypothesizing that POL5551 may mobilize tumor cells from their microenvironment and sensitize them to chemotherapy, we used a "chemotherapy framing" dosing strategy."( CXCR4 Protein Epitope Mimetic Antagonist POL5551 Disrupts Metastasis and Enhances Chemotherapy Effect in Triple-Negative Breast Cancer.
Ademuyiwa, FO; Aft, RL; Amend, SR; Bauer, M; Chevalier, E; Dembowsky, K; Douglas, GJ; Esser, AK; Fontana, F; Hurchla, MA; Luker, GD; Luker, KE; Mudalagiriyappa, C; Pluard, T; Romagnoli, B; Su, X; Tuffin, G; Weilbaecher, KN; Xiang, J; Zimmermann, J, 2015)		0.42
"9%) for eribulin than for capecitabine using the standard dosing schedule."( Phase II, Multicenter, Single-Arm, Feasibility Study of Eribulin Combined With Capecitabine for Adjuvant Treatment in Estrogen Receptor-Positive, Early-Stage Breast Cancer.
Berrak, E; Hoffman, AD; Jones, VE; McIntyre, K; O'Shaughnessy, J; Smith, JW; Song, JX; Vukelja, S, 2016)		0.43
"Eribulin plus capecitabine with standard or weekly dosing schedules is feasible in patients with early-stage, HER2-negative, ER-positive breast cancer."( Phase II, Multicenter, Single-Arm, Feasibility Study of Eribulin Combined With Capecitabine for Adjuvant Treatment in Estrogen Receptor-Positive, Early-Stage Breast Cancer.
Berrak, E; Hoffman, AD; Jones, VE; McIntyre, K; O'Shaughnessy, J; Smith, JW; Song, JX; Vukelja, S, 2016)		0.43
" Therefore, we retrospectively investigated the optimal approach for Eri dose adjustment and/or dosage interval adjustment."( Dose Reduction versus Dose-interval Prolongation in Eribulin Mesilate Monotherapy in Patients with Metastatic Breast Cancer: A Retrospective Comparative Study.
Ban, A; Hisada, T; Itakura, Y; Katsuragawa, K; Mishima, E; Mizutani, M; Nagamatsu, H; Oshima, Y; Sasaki, T; Tsukiyama, I; Yoshioka, Y, 2016)		0.43
" Consistent with the acute dosing study, both drugs persisted in peripheral nervous tissues for weeks, in contrast to their rapid clearance from plasma."( Sustained Accumulation of Microtubule-Binding Chemotherapy Drugs in the Peripheral Nervous System: Correlations with Time Course and Neurotoxic Severity.
DesJardins, C; Lai, G; Littlefield, BA; Nomoto, K; Reyderman, L; Slusher, BS; Vornov, JJ; Wong, N; Wozniak, KM; Wu, Y; Yu, Y, 2016)		0.43
"Current evidence suggests that a triweekly schedule of ixabepilone is more effective than weekly dosing in improving ORR."( Systematic review of ixabepilone for treating metastatic breast cancer.
Li, J; Ren, J; Sun, W, 2017)		0.46
" A modified biweekly dosing schedule of eribulin was assessed for efficacy as well as improvements in hematologic toxicity."( Phase II Study of Eribulin Mesylate Administered Biweekly in Patients With Human Epidermal Growth Factor Receptor-2-negative Metastatic Breast Cancer.
Almonte, A; He, Y; Irwin, A; Jensen, L; Misir, S; O'Shaughnessy, J; Olivo, M; Smith, J; Tedesco, K; Xie, R; Zhu, W, 2020)		0.56
" The drug effect score (DES) was calculated from the dose-response of each drug for comparison among drugs or samples."( Aurora B kinase as a therapeutic target in acute lymphoblastic leukemia.
Goto, H; Goto, S; Hamanoue, S; Inukai, T; Ito, M; Iwasaki, F; Keino, D; Kumamoto, T; Miyagawa, N; Nagai, J; Sakurai, Y; Shiomi, M; Yokosuka, T; Yoshino, Y, 2020)		0.56
" We demonstrate steep dose-response for eribulin in osteosarcoma PDX models, implying that any deviation from achievement of effective concentrations may have a significant impact on activity."( Dose-response effect of eribulin in preclinical models of osteosarcoma by the pediatric preclinical testing consortium.
Erickson, S; Gatto, G; Gill, J; Gorlick, R; Harrison, DJ; Houghton, P; Kolb, EA; Kurmasheva, R; Roth, M; Rowshan, S; Smith, MA; Teicher, B; Zhang, W; Zhang, Z, 2020)		0.56
" In populations such as patients with metastatic breast cancer, in which metastatic infiltration is the predominant cause of hepatic impairment, using Child-Pugh score may be problematic; in clinical practice, it has been more common for oncologists to make dosing decisions based on LFTs."( Eribulin, Child-Pugh score, and liver-function tests: lessons from pivotal breast cancer studies 301 and 305.
He, Y; Macpherson, IR; Palmieri, C, 2021)		0.62
" Further investigations are required to establish appropriate dosage and clinical utility of MORAb-202."( First-in-Human Phase 1 Study of MORAb-202, an Antibody-Drug Conjugate Comprising Farletuzumab Linked to Eribulin Mesylate, in Patients with Folate Receptor-α-Positive Advanced Solid Tumors.
Fujiwara, Y; Furuuchi, K; Ikezawa, H; Koyama, T; Miura, T; Nakajima, R; Nomoto, M; Sato, J; Shimizu, T; Shimomura, A; Tamura, K; Yamamoto, N; Yonemori, K, 2021)		0.62
"This pharmacokinetic/pharmacodynamic (PK/PD) study was conducted to establish the effect of different G-CSF regimens on neutropenia's incidence for patients treated by eribulin, to propose an optimal G-CSF dosing schedule."( Optimization of G-CSF dosing schedule in patients treated with eribulin: a modeling approach.
Bellio, H; Bonnin, N; Desmoulins, I; Freyer, G; Fumoleau, P; Hennequin, A; Ilie, S; Isambert, N; Ladoire, S; Lorgis, V; Macaire, P; Reda, M; Rederstorff, E; Schmitt, A; Uwer, L; You, B, 2022)		0.72
" Final model estimates were used to calculate neutropenia's incidence following different G-CSF dosing schedules for 1000 virtual subjects."( Optimization of G-CSF dosing schedule in patients treated with eribulin: a modeling approach.
Bellio, H; Bonnin, N; Desmoulins, I; Freyer, G; Fumoleau, P; Hennequin, A; Ilie, S; Isambert, N; Ladoire, S; Lorgis, V; Macaire, P; Reda, M; Rederstorff, E; Schmitt, A; Uwer, L; You, B, 2022)		0.72
" Schedule and dosage modifications were common, but toxicity rarely led to treatment discontinuation."( Tolerability of Eribulin and correlation between polymorphisms and neuropathy in an unselected population of female patients with metastatic breast cancer: results of the multicenter, single arm, phase IV PAINTER study.
Bertolini, AS; Bramati, A; Cassano, A; Cavanna, L; Ciccarese, M; Collovà, E; Cretella, E; Damia, G; Fabi, A; Farina, G; Ferraris, E; Garrone, O; Generali, DG; Guffanti, F; La Verde, N; Legramandi, L; Meattini, I; Moretti, A; Nunzi, M; Poletto, E; Romagnoli, E; Rulli, E; Santini, D; Scandurra, G; Torri, V; Vici, P, 2022)		0.72
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
antineoplastic agentA substance that inhibits or prevents the proliferation of neoplasms.
microtubule-destabilising agentAny substance that interacts with tubulin to inhibit polymerisation of microtubules.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (6)

ClassDescription
macrocycleA cyclic compound containing nine or more atoms as part of the cyclic system.
polyetherAny ether that contains more than one ether linkage.
polycyclic ether
cyclic ketone
primary amino compoundA compound formally derived from ammonia by replacing one hydrogen atom by an organyl group.
cyclic ketalA ketal in the molecule of which the ketal carbon and one or both oxygen atoms thereon are members of a ring.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (23)

Assay IDTitleYearJournalArticle
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID579983Cytotoxicity against human DLD1 cells2011Bioorganic & medicinal chemistry letters, Mar-15, Volume: 21, Issue:6
Novel second generation analogs of eribulin. Part II: Orally available and active against resistant tumors in vivo.
AID579984Cytotoxicity against human HCT15 cells2011Bioorganic & medicinal chemistry letters, Mar-15, Volume: 21, Issue:6
Novel second generation analogs of eribulin. Part II: Orally available and active against resistant tumors in vivo.
AID579808Cytotoxicity against human IMR90 cells up to 1 uM2011Bioorganic & medicinal chemistry letters, Mar-15, Volume: 21, Issue:6
Novel second generation analogs of eribulin. Part I: Compounds containing a lipophilic C32 side chain overcome P-glycoprotein susceptibility.
AID579809Antitumor activity against human LOX cells xenografted in athymic mouse assessed as inhibition of tumor growth at 0.1 mg/kg, iv qd administered 5 days a week for 2 weeks measured up to 2 weeks2011Bioorganic & medicinal chemistry letters, Mar-15, Volume: 21, Issue:6
Novel second generation analogs of eribulin. Part I: Compounds containing a lipophilic C32 side chain overcome P-glycoprotein susceptibility.
AID1204868Toxicity in metastatic breast cancer patient assessed as neuropathy rate2015European journal of medicinal chemistry, Apr-13, Volume: 94Selected hybrid natural products as tubulin modulators.
AID1204870Toxicity in metastatic breast cancer patient assessed as incidence of peripheral neuropathy2015European journal of medicinal chemistry, Apr-13, Volume: 94Selected hybrid natural products as tubulin modulators.
AID579988Clearance in BALB/c mouse at 10 mg/kg, iv2011Bioorganic & medicinal chemistry letters, Mar-15, Volume: 21, Issue:6
Novel second generation analogs of eribulin. Part II: Orally available and active against resistant tumors in vivo.
AID579985AUC (0 to infinity) in BALB/c mouse at 10 mg/kg2011Bioorganic & medicinal chemistry letters, Mar-15, Volume: 21, Issue:6
Novel second generation analogs of eribulin. Part II: Orally available and active against resistant tumors in vivo.
AID579980Cytotoxicity against human MES-SA cells2011Bioorganic & medicinal chemistry letters, Mar-15, Volume: 21, Issue:6
Novel second generation analogs of eribulin. Part II: Orally available and active against resistant tumors in vivo.
AID1204869Toxicity in metastatic breast cancer patient assessed as incidence of neuropathy2015European journal of medicinal chemistry, Apr-13, Volume: 94Selected hybrid natural products as tubulin modulators.
AID579986Half life in BALB/c mouse at 10 mg/kg2011Bioorganic & medicinal chemistry letters, Mar-15, Volume: 21, Issue:6
Novel second generation analogs of eribulin. Part II: Orally available and active against resistant tumors in vivo.
AID579989Oral bioavailability in BALB/c mouse at 10 mg/kg2011Bioorganic & medicinal chemistry letters, Mar-15, Volume: 21, Issue:6
Novel second generation analogs of eribulin. Part II: Orally available and active against resistant tumors in vivo.
AID579981Cytotoxicity against human MES-SA/Dx5-Rx1 cells2011Bioorganic & medicinal chemistry letters, Mar-15, Volume: 21, Issue:6
Novel second generation analogs of eribulin. Part II: Orally available and active against resistant tumors in vivo.
AID579803Antiproliferative activity against human MES-SA cells assessed as growth inhibition2011Bioorganic & medicinal chemistry letters, Mar-15, Volume: 21, Issue:6
Novel second generation analogs of eribulin. Part I: Compounds containing a lipophilic C32 side chain overcome P-glycoprotein susceptibility.
AID579807Antiproliferative activity against human HCT15 cells assessed as growth inhibition2011Bioorganic & medicinal chemistry letters, Mar-15, Volume: 21, Issue:6
Novel second generation analogs of eribulin. Part I: Compounds containing a lipophilic C32 side chain overcome P-glycoprotein susceptibility.
AID579806Antiproliferative activity against human DLD1 cells assessed as growth inhibition2011Bioorganic & medicinal chemistry letters, Mar-15, Volume: 21, Issue:6
Novel second generation analogs of eribulin. Part I: Compounds containing a lipophilic C32 side chain overcome P-glycoprotein susceptibility.
AID579804Antiproliferative activity against P-gp overexpressing human MES-SA/Dx5-Rx1 cells assessed as growth inhibition2011Bioorganic & medicinal chemistry letters, Mar-15, Volume: 21, Issue:6
Novel second generation analogs of eribulin. Part I: Compounds containing a lipophilic C32 side chain overcome P-glycoprotein susceptibility.
AID579982Fold resistant ratio of IC50 for human MES-SA cells to IC50 for MES-SA/Dx5-Rx1 cells2011Bioorganic & medicinal chemistry letters, Mar-15, Volume: 21, Issue:6
Novel second generation analogs of eribulin. Part II: Orally available and active against resistant tumors in vivo.
AID579805Fold resistance, ratio of IC50 for antiproliferative activity for human MES-SA cells to IC50 for antiproliferative activity for P-gp overexpressing human MES-SA/Dx5-Rx1cells2011Bioorganic & medicinal chemistry letters, Mar-15, Volume: 21, Issue:6
Novel second generation analogs of eribulin. Part I: Compounds containing a lipophilic C32 side chain overcome P-glycoprotein susceptibility.
AID579995Tmax in BALB/c mouse at 10 mg/kg2011Bioorganic & medicinal chemistry letters, Mar-15, Volume: 21, Issue:6
Novel second generation analogs of eribulin. Part II: Orally available and active against resistant tumors in vivo.
AID579987Volume of distribution at steady state in BALB/c mouse at 10 mg/kg, iv2011Bioorganic & medicinal chemistry letters, Mar-15, Volume: 21, Issue:6
Novel second generation analogs of eribulin. Part II: Orally available and active against resistant tumors in vivo.
AID1346118Human tubulin beta class I (Tubulins)2011Bioorganic & medicinal chemistry letters, Mar-15, Volume: 21, Issue:6
Novel second generation analogs of eribulin. Part III: Blood-brain barrier permeability and in vivo activity in a brain tumor model.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (545)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's20 (3.67)29.6817
2010's352 (64.59)24.3611
2020's173 (31.74)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 9.48

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index9.48 (24.57)
Research Supply Index6.52 (2.92)
Research Growth Index6.00 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (9.48)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials113 (19.93%)5.53%
Reviews67 (11.82%)6.00%
Case Studies74 (13.05%)4.05%
Observational22 (3.88%)0.25%
Other291 (51.32%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
carbamates
[no description available]		2.0210amino-acid anion
pteridines
[no description available]		2.1110azaarene;
mancude organic heterobicyclic parent;
ortho-fused heteroarene;
pteridines
2,2'-dipyridyl
2,2'-Dipyridyl: A reagent used for the determination of iron.. 2,2'-bipyridine : A bipyridine in which the two pyridine moieties are linked by a bond between positions C-2 and C-2'.		2.1110bipyridinechelator;
ferroptosis inhibitor
deferoxamine
Deferoxamine: Natural product isolated from Streptomyces pilosus. It forms iron complexes and is used as a chelating agent, particularly in the mesylate form.. desferrioxamine B : An acyclic desferrioxamine that is butanedioic acid in which one of the carboxy groups undergoes formal condensation with the primary amino group of N-(5-aminopentyl)-N-hydroxyacetamide and the second carboxy group undergoes formal condensation with the hydroxyamino group of N(1)-(5-aminopentyl)-N(1)-hydroxy-N(4)-[5-(hydroxyamino)pentyl]butanediamide. It is a siderophore native to Streptomyces pilosus biosynthesised by the DesABCD enzyme cluster as a high affinity Fe(III) chelator.		2.2510acyclic desferrioxaminebacterial metabolite;
ferroptosis inhibitor;
iron chelator;
siderophore
donepezil
Donepezil: An indan and piperidine derivative that acts as a selective and reversible inhibitor of ACETYLCHOLINESTERASE. Donepezil is highly selective for the central nervous system and is used in the management of mild to moderate DEMENTIA in ALZHEIMER DISEASE.. donepezil : A racemate comprising equimolar amounts of (R)- and (S)-donepezil. A centrally acting reversible acetylcholinesterase inhibitor, its main therapeutic use is in the treatment of Alzheimer's disease where it is used to increase cortical acetylcholine.. 2-[(1-benzylpiperidin-4-yl)methyl]-5,6-dimethoxyindan-1-one : A member of the class of indanones that is 5,6-dimethoxyindan-1-one which is substituted at position 2 by an (N-benzylpiperidin-4-yl)methyl group.		2.1710aromatic ether;
indanones;
piperidines;
racemate		EC 3.1.1.7 (acetylcholinesterase) inhibitor;
EC 3.1.1.8 (cholinesterase) inhibitor;
nootropic agent
fluphenazine
[no description available]		2.5720N-alkylpiperazine;
organofluorine compound;
phenothiazines		anticoronaviral agent;
dopaminergic antagonist;
phenothiazine antipsychotic drug
fluorouracil
Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.. 5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.		9.11137nucleobase analogue;
organofluorine compound		antimetabolite;
antineoplastic agent;
environmental contaminant;
immunosuppressive agent;
radiosensitizing agent;
xenobiotic
ifosfamide
[no description available]		3.9630ifosfamidesalkylating agent;
antineoplastic agent;
environmental contaminant;
immunosuppressive agent;
xenobiotic
ketoconazole
1-acetyl-4-(4-{[2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)piperazine : A dioxolane that is 1,3-dioxolane which is substituted at positions 2, 2, and 4 by imidazol-1-ylmethyl, 2,4-dichlorophenyl, and [para-(4-acetylpiperazin-1-yl)phenoxy]methyl groups, respectively.		3.4711dichlorobenzene;
dioxolane;
ether;
imidazoles;
N-acylpiperazine;
N-arylpiperazine
nifedipine
Nifedipine: A potent vasodilator agent with calcium antagonistic action. It is a useful anti-anginal agent that also lowers blood pressure.		2.0410C-nitro compound;
dihydropyridine;
methyl ester		calcium channel blocker;
human metabolite;
tocolytic agent;
vasodilator agent
oxonic acid
Oxonic Acid: Antagonist of urate oxidase.		3.5111,3,5-triazines;
monocarboxylic acid
tegafur
[no description available]		3.511organohalogen compound;
pyrimidines
thalidomide
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.. thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.. 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.		3.3110phthalimides;
piperidones
tolbutamide
Tolbutamide: A sulphonylurea hypoglycemic agent with actions and uses similar to those of CHLORPROPAMIDE. (From Martindale, The Extra Pharmacopoeia, 30th ed, p290). tolbutamide : An N-sulfonylurea that consists of 1-butylurea having a tosyl group attached at the 3-position.		2.0410N-sulfonylureahuman metabolite;
hypoglycemic agent;
insulin secretagogue;
potassium channel blocker
colchicine
(S)-colchicine : A colchicine that has (S)-configuration. It is a secondary metabolite, has anti-inflammatory properties and is used to treat gout, crystal-induced joint inflammation, familial Mediterranean fever, and many other conditions.		3.6820alkaloid;
colchicine		anti-inflammatory agent;
gout suppressant;
mutagen
cytarabine
[no description available]		4.2220beta-D-arabinoside;
monosaccharide derivative;
pyrimidine nucleoside		antimetabolite;
antineoplastic agent;
antiviral agent;
immunosuppressive agent
3-hydroxybutanal
[no description available]		2.1110
tetrahydrofuran
oxolane : A cyclic ether that is butane in which one hydrogen from each methyl group is substituted by an oxygen.		2.1310cyclic ether;
oxolanes;
saturated organic heteromonocyclic parent;
volatile organic compound		polar aprotic solvent
thiophenes
Thiophenes: A monocyclic heteroarene furan in which the oxygen atom is replaced by a sulfur.. thiophenes : Compounds containing at least one thiophene ring.		2.1110mancude organic heteromonocyclic parent;
monocyclic heteroarene;
thiophenes;
volatile organic compound		non-polar solvent
pyrazolanthrone
pyrazolanthrone: JNK (c-Jun N-terminal kinase) inhibitor; structure in first source. anthra[1,9-cd]pyrazol-6(2H)-one : A member of the class of anthrapyrazoles that is anthra[1,9-cd]pyrazole substituted at position 6 by an oxo group. An inhibitor of c-Jun N-terminal kinase.		2.2510anthrapyrazole;
aromatic ketone;
cyclic ketone		antineoplastic agent;
c-Jun N-terminal kinase inhibitor;
geroprotector
quinazolines
Quinazolines: A group of aromatic heterocyclic compounds that contain a bicyclic structure with two fused six-membered aromatic rings, a benzene ring and a pyrimidine ring.. quinazoline : A mancude organic heterobicyclic parent that is naphthalene in which the carbon atoms at positions 1 and 3 have been replaced by nitrogen atoms.. quinazolines : Any organic heterobicyclic compound based on a quinazoline skeleton and its substituted derivatives.		6.4241azaarene;
mancude organic heterobicyclic parent;
ortho-fused heteroarene;
quinazolines
acridines
Acridines: Compounds that include the structure of acridine.. acridine : A polycyclic heteroarene that is anthracene in which one of the central CH groups is replaced by a nitrogen atom.		2.1510acridines;
mancude organic heterotricyclic parent;
polycyclic heteroarene		genotoxin
indazoles
Indazoles: A group of heterocyclic aromatic organic compounds consisting of the fusion of BENZENE and PYRAZOLES.		5.570indazole
isoxazoles
Isoxazoles: Azoles with an OXYGEN and a NITROGEN next to each other at the 1,2 positions, in contrast to OXAZOLES that have nitrogens at the 1,3 positions.. isoxazole : A monocyclic heteroarene with a structure consisting of a 5-membered ring containing three carbon atoms and an oxygen and nitrogen atom adjacent to each other. It is the parent of the class of isoxazoles.. isoxazoles : Oxazoles in which the N and O atoms are adjacent.		2.2510isoxazoles;
mancude organic heteromonocyclic parent;
monocyclic heteroarene
hydrazine
diamine : Any polyamine that contains two amino groups.		2.1510azane;
hydrazines		EC 4.3.1.10 (serine-sulfate ammonia-lyase) inhibitor
1,4-cyclohexadiene
[no description available]		2.1310cyclohexadiene
vinblastine
[no description available]		2.4720
deoxycytidine
[no description available]		12.112514pyrimidine 2'-deoxyribonucleosideEscherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
arsenic trioxide
Arsenic Trioxide: An inorganic compound with the chemical formula As2O3 that is used for the treatment of ACUTE PROMYELOCYTIC LEUKEMIA in patients who have relapsed from, or are resistant to, conventional drug therapy.		2.1310
manganese
Manganese: A trace element with atomic symbol Mn, atomic number 25, and atomic weight 54.94. It is concentrated in cell mitochondria, mostly in the pituitary gland, liver, pancreas, kidney, and bone, influences the synthesis of mucopolysaccharides, stimulates hepatic synthesis of cholesterol and fatty acids, and is a cofactor in many enzymes, including arginase and alkaline phosphatase in the liver. (From AMA Drug Evaluations Annual 1992, p2035). manganese(4+) : A manganese cation that is monoatomic and has a formal charge of +4.		2.1110elemental manganese;
manganese group element atom		Escherichia coli metabolite;
micronutrient
platinum
Platinum: A heavy, soft, whitish metal, resembling tin, with atomic number 78, atomic weight 195.084, symbol Pt. It is used in manufacturing equipment for laboratory and industrial use. It occurs as a black powder (platinum black) and as a spongy substance (spongy platinum) and may have been known in Pliny's time as alutiae.		6.4533elemental platinum;
nickel group element atom;
platinum group metal atom
chromium
Chromium: A trace element that plays a role in glucose metabolism. It has the atomic symbol Cr, atomic number 24, and atomic weight 52. According to the Fourth Annual Report on Carcinogens (NTP85-002,1985), chromium and some of its compounds have been listed as known carcinogens.. chromium ion : An chromium atom having a net electric charge.. chromium atom : A chromium group element atom that has atomic number 24.		2.1110chromium group element atom;
metal allergen		micronutrient
camptothecin
NSC 100880: carboxylate (opened lactone) form of camptothecin; RN refers to (S)-isomer; structure given in first source		4.1220delta-lactone;
pyranoindolizinoquinoline;
quinoline alkaloid;
tertiary alcohol		antineoplastic agent;
EC 5.99.1.2 (DNA topoisomerase) inhibitor;
genotoxin;
plant metabolite
paclitaxel
Taxus: Genus of coniferous yew trees or shrubs, several species of which have medicinal uses. Notable is the Pacific yew, Taxus brevifolia, which is used to make the anti-neoplastic drug taxol (PACLITAXEL).		13.054412taxane diterpenoid;
tetracyclic diterpenoid		antineoplastic agent;
human metabolite;
metabolite;
microtubule-stabilising agent
vindesine
Vindesine: Vinblastine derivative with antineoplastic activity against CANCER. Major side effects are myelosuppression and neurotoxicity. Vindesine is used extensively in chemotherapy protocols (ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS).		2.2110methyl ester;
organic heteropentacyclic compound;
organic heterotetracyclic compound;
primary carboxamide;
tertiary alcohol;
tertiary amino compound;
vinca alkaloid		antineoplastic agent
epirubicin
Epirubicin: An anthracycline which is the 4'-epi-isomer of doxorubicin. The compound exerts its antitumor effects by interference with the synthesis and function of DNA.		3.811aminoglycoside;
anthracycline antibiotic;
anthracycline;
deoxy hexoside;
monosaccharide derivative;
p-quinones;
primary alpha-hydroxy ketone;
tertiary alpha-hydroxy ketone		antimicrobial agent;
antineoplastic agent;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor
topotecan
Topotecan: An antineoplastic agent used to treat ovarian cancer. It works by inhibiting DNA TOPOISOMERASES, TYPE I.. topotecan : A pyranoindolizinoquinoline used as an antineoplastic agent. It is a derivative of camptothecin and works by binding to the topoisomerase I-DNA complex and preventing religation of these 328 single strand breaks.		2.110pyranoindolizinoquinolineantineoplastic agent;
EC 5.99.1.2 (DNA topoisomerase) inhibitor
gemcitabine
gemcitabine : A 2'-deoxycytidine having geminal fluoro substituents in the 2'-position. An inhibitor of ribonucleotide reductase, gemcitabine is used in the treatment of various carcinomas, particularly non-small cell lung cancer, pancreatic cancer, bladder cancer and breast cancer.		10.73179organofluorine compound;
pyrimidine 2'-deoxyribonucleoside		antimetabolite;
antineoplastic agent;
antiviral drug;
DNA synthesis inhibitor;
EC 1.17.4.1 (ribonucleoside-diphosphate reductase) inhibitor;
environmental contaminant;
immunosuppressive agent;
photosensitizing agent;
prodrug;
radiosensitizing agent;
xenobiotic
aripiprazole
Aripiprazole: A piperazine and quinolone derivative that is used primarily as an antipsychotic agent. It is a partial agonist of SEROTONIN RECEPTOR, 5-HT1A and DOPAMINE D2 RECEPTORS, where it also functions as a post-synaptic antagonist, and an antagonist of SEROTONIN RECEPTOR, 5-HT2A. It is used for the treatment of SCHIZOPHRENIA and BIPOLAR DISORDER, and as an adjunct therapy for the treatment of depression.. aripiprazole : An N-arylpiperazine that is piperazine substituted by a 4-[(2-oxo-1,2,3,4-tetrahydroquinolin-7-yl)oxy]butyl group at position 1 and by a 2,3-dichlorophenyl group at position 4. It is an antipsychotic drug used for the treatment of Schizophrenia, and other mood disorders.		2.6320aromatic ether;
delta-lactam;
dichlorobenzene;
N-alkylpiperazine;
N-arylpiperazine;
quinolone		drug metabolite;
H1-receptor antagonist;
second generation antipsychotic;
serotonergic agonist
duloxetine hydrochloride
Duloxetine Hydrochloride: A thiophene derivative and selective NEUROTRANSMITTER UPTAKE INHIBITOR for SEROTONIN and NORADRENALINE (SNRI). It is an ANTIDEPRESSIVE AGENT and ANXIOLYTIC, and is also used for the treatment of pain in patients with DIABETES MELLITUS and FIBROMYALGIA.. (S)-duloxetine hydrochloride : A duloxetine hydrochloride in which the duloxetine moiety has S configuration.		2.1110duloxetine hydrochlorideantidepressant
irinotecan
[no description available]		2.7620carbamate ester;
delta-lactone;
N-acylpiperidine;
pyranoindolizinoquinoline;
ring assembly;
tertiary alcohol;
tertiary amino compound		antineoplastic agent;
apoptosis inducer;
EC 5.99.1.2 (DNA topoisomerase) inhibitor;
prodrug
capecitabine
Capecitabine: A deoxycytidine derivative and fluorouracil PRODRUG that is used as an ANTINEOPLASTIC ANTIMETABOLITE in the treatment of COLON CANCER; BREAST CANCER and GASTRIC CANCER.. capecitabine : A carbamate ester that is cytidine in which the hydrogen at position 5 is replaced by fluorine and in which the amino group attached to position 4 is converted into its N-(penyloxy)carbonyl derivative. Capecitabine is a antineoplastic agent used in the treatment of cancers.		12.352915carbamate ester;
cytidines;
organofluorine compound		antimetabolite;
antineoplastic agent;
prodrug
nelfinavir
Nelfinavir: A potent HIV protease inhibitor. It is used in combination with other antiviral drugs in the treatment of HIV in both adults and children.. nelfinavir : An aryl sulfide that is used (as its mesylate salt) for treatment of HIV and also exhibits some anticancer properties.		2.2110aryl sulfide;
benzamides;
organic heterobicyclic compound;
phenols;
secondary alcohol;
tertiary amino compound		antineoplastic agent;
HIV protease inhibitor
triazoles
Triazoles: Heterocyclic compounds containing a five-membered ring with two carbon atoms and three nitrogen atoms with the molecular formula C2H3N3.. triazoles : An azole in which the five-membered heterocyclic aromatic skeleton contains three N atoms and two C atoms.		2.15101,2,3-triazole
lopinavir
[no description available]		2.2110amphetamines;
dicarboxylic acid diamide		anticoronaviral agent;
antiviral drug;
HIV protease inhibitor
fulvestrant
Fulvestrant: An estradiol derivative and estrogen receptor antagonist that is used for the treatment of estrogen receptor-positive, locally advanced or metastatic breast cancer.. fulvestrant : A 3-hydroxy steroid that is 17beta-estradiol in which the 7alpha hydrogen has been replaced by a nonyl group in which one of the hydrogens of the terminal methyl has been replaced by a (4,4,5,5,5-pentafluoropentyl)sulfinyl group. An estrogen receptor antagonist, it is used in the treatment of breast cancer.		3.064017beta-hydroxy steroid;
3-hydroxy steroid;
organofluorine compound;
sulfoxide		antineoplastic agent;
estrogen antagonist;
estrogen receptor antagonist
fingolimod hydrochloride
Fingolimod Hydrochloride: A sphingosine-derivative and IMMUNOSUPPRESSIVE AGENT that blocks the migration and homing of LYMPHOCYTES to the CENTRAL NERVOUS SYSTEM through its action on SPHINGOSINE 1-PHOSPHATE RECEPTORS. It is used in the treatment of MULTIPLE SCLEROSIS.. fingolimod hydrochloride : The hydrochloride salt of 2-amino-2-[2-(4-octylphenyl) ethyl]-1,3-propanediol (fingolimod).		3.1610hydrochlorideimmunosuppressive agent;
prodrug;
sphingosine-1-phosphate receptor agonist
ecteinascidin 743
[no description available]		7.63200acetate ester;
azaspiro compound;
bridged compound;
hemiaminal;
isoquinoline alkaloid;
lactone;
organic heteropolycyclic compound;
organic sulfide;
oxaspiro compound;
polyphenol;
tertiary amino compound		alkylating agent;
angiogenesis modulating agent;
anti-inflammatory agent;
antineoplastic agent;
marine metabolite
elacridar
Elacridar: inhibitor of MDR1 PROTEIN; structure given in first source		2.1510
abiraterone
[no description available]		2.05103beta-hydroxy-Delta(5)-steroid;
3beta-sterol;
pyridines		antineoplastic agent;
EC 1.14.99.9 (steroid 17alpha-monooxygenase) inhibitor
docetaxel anhydrous
Docetaxel: A semisynthetic analog of PACLITAXEL used in the treatment of locally advanced or metastatic BREAST NEOPLASMS and NON-SMALL CELL LUNG CANCER.. docetaxel anhydrous : A tetracyclic diterpenoid that is paclitaxel with the N-benzyloxycarbonyl group replaced by N-tert-butoxycarbonyl, and the acetoxy group at position 10 replaced by a hydroxy group.		5.4341secondary alpha-hydroxy ketone;
tetracyclic diterpenoid		antimalarial;
antineoplastic agent;
photosensitizing agent
patellamide a
patellamide A: a cytotoxic cyclic peptide from ascidian Lissoclinum patella; structure given in first source		2.0310cyclic peptide
biotin
vitamin B7 : Any member of a group of vitamers that belong to the chemical structural class called biotins that exhibit biological activity against vitamin B7 deficiency. Vitamin B7 deficiency is very rare in individuals who take a normal balanced diet. Foods rich in biotin are egg yolk, liver, cereals, vegetables (spinach, mushrooms) and rice. Symptoms associated with vitamin B7 deficiency include thinning hair, scaly skin rashes around eyes, nose and mouth, and brittle nails. The vitamers include biotin and its ionized and salt forms.		3.820biotins;
vitamin B7		coenzyme;
cofactor;
Escherichia coli metabolite;
fundamental metabolite;
human metabolite;
mouse metabolite;
nutraceutical;
prosthetic group;
Saccharomyces cerevisiae metabolite
erlotinib hydrochloride
[no description available]		4.411hydrochloride;
terminal acetylenic compound		antineoplastic agent;
protein kinase inhibitor
lapatinib
[no description available]		5.2731furans;
organochlorine compound;
organofluorine compound;
quinazolines		antineoplastic agent;
tyrosine kinase inhibitor
deferasirox
Deferasirox: A triazole and benzoate derivative that acts as a selective iron chelator. It is used in the management of chronic IRON OVERLOAD due to blood transfusion or non-transfusion dependent THALASSEMIA.. deferasirox : A member of the class of triazoles, deferasirox is 1,2,4-triazole substituted by a 4-carboxyphenyl group at position 1 and by 2-hydroxyphenyl groups at positions 3 and 5. An orally active iron chelator, it is used to manage chronic iron overload in patients receiving long-term blood transfusions.		2.2510benzoic acids;
monocarboxylic acid;
phenols;
triazoles		iron chelator
sorafenib
[no description available]		5.0821(trifluoromethyl)benzenes;
aromatic ether;
monochlorobenzenes;
phenylureas;
pyridinecarboxamide		angiogenesis inhibitor;
anticoronaviral agent;
antineoplastic agent;
EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor;
ferroptosis inducer;
tyrosine kinase inhibitor
batabulin
batabulin: disrupts microtubule polymerization by binding certain beta-tubulin isotypes; effective against some multidrug-resistant tumors; structure in first source		3.2310
demecolcine
Demecolcine: An alkaloid isolated from Colchicum autumnale L. and used as an antineoplastic.. (-)-demecolcine : A secondary amino compound that is (S)-colchicine in which the N-acetyl group is replaced by an N-methyl group. Isolable from the autumn crocus, Colchicum autumnale, it is less toxic than colchicine and is used as an antineoplastic.		3.2310alkaloid;
secondary amino compound		antineoplastic agent;
microtubule-destabilising agent
homoharringtonine
Homoharringtonine: Semisynthetic derivative of harringtonine that acts as a protein synthesis inhibitor and induces APOPTOSIS in tumor cells. It is used in the treatment of MYELOID LEUKEMIA, CHRONIC.. omacetaxine mepesuccinate : A cephalotaxine-derived alkaloid ester obtained from Cephalotaxus harringtonia; used for the treatment of chronic or accelerated phase chronic myeloid leukaemia.		3.2110alkaloid ester;
enol ether;
organic heteropentacyclic compound;
tertiary alcohol		anticoronaviral agent;
antineoplastic agent;
apoptosis inducer;
protein synthesis inhibitor
withanolides
Withanolides: Ergostane derivatives of 28 carbons with oxygens at C1, C22, and C26 positions and the side chain cyclized. They are found in WITHANIA plant genus and have cytotoxic and other effects.		3.2110
bortezomib
[no description available]		2.3110amino acid amide;
L-phenylalanine derivative;
pyrazines		antineoplastic agent;
antiprotozoal drug;
protease inhibitor;
proteasome inhibitor
ritonavir
Ritonavir: An HIV protease inhibitor that works by interfering with the reproductive cycle of HIV. It also inhibits CYTOCHROME P-450 CYP3A.. ritonavir : An L-valine derivative that is L-valinamide in which alpha-amino group has been acylated by a [(2-isopropyl-1,3-thiazol-4-yl)methyl]methylcarbamoyl group and in which a hydrogen of the carboxamide amino group has been replaced by a (2R,4S,5S)-4-hydroxy-1,6-diphenyl-5-{[(1,3-thiazol-5-ylmethoxy)carbonyl]amino}hexan-2-yl group. A CYP3A inhibitor and antiretroviral drug from the protease inhibitor class used to treat HIV infection and AIDS, it is often used as a fixed-dose combination with another protease inhibitor, lopinavir. Also used in combination with dasabuvir sodium hydrate, ombitasvir and paritaprevir (under the trade name Viekira Pak) for treatment of chronic hepatitis C virus genotype 1 infection as well as cirrhosis of the liver.		2.21101,3-thiazoles;
carbamate ester;
carboxamide;
L-valine derivative;
ureas		antiviral drug;
environmental contaminant;
HIV protease inhibitor;
xenobiotic
carboplatin
[no description available]		6.9453
epothilone a
Epothilones: A group of 16-member MACROLIDES which stabilize MICROTUBULES in a manner similar to PACLITAXEL. They were originally found in the myxobacterium Sorangium cellulosum, now renamed to Polyangium (MYXOCOCCALES).		9.64142epothilone;
epoxide		antineoplastic agent;
metabolite;
microtubule-stabilising agent;
tubulin modulator
afimoxifene
afimoxifene : A tertiary amino compound that is tamoxifen in which the phenyl group which is in a Z- relationship to the ethyl substituent is hydroxylated at the para- position. It is the active metabolite of tamoxifen.		2.1310phenols;
tertiary amino compound		antineoplastic agent;
estrogen receptor antagonist;
metabolite
dactinomycin
Dactinomycin: A compound composed of a two CYCLIC PEPTIDES attached to a phenoxazine that is derived from STREPTOMYCES parvullus. It binds to DNA and inhibits RNA synthesis (transcription), with chain elongation more sensitive than initiation, termination, or release. As a result of impaired mRNA production, protein synthesis also declines after dactinomycin therapy. (From AMA Drug Evaluations Annual, 1993, p2015)		2.3110actinomycinmutagen
stilbenes
Stilbenes: Organic compounds that contain 1,2-diphenylethylene as a functional group.. trans-stilbene : The trans-isomer of stilbene.		3.2310stilbene
tamoxifen
[no description available]		2.9130stilbenoid;
tertiary amino compound		angiogenesis inhibitor;
antineoplastic agent;
bone density conservation agent;
EC 1.2.3.1 (aldehyde oxidase) inhibitor;
EC 2.7.11.13 (protein kinase C) inhibitor;
estrogen antagonist;
estrogen receptor antagonist;
estrogen receptor modulator
u 0126
U 0126: protein kinase kinase inhibitor; structure in first source		2.2510aryl sulfide;
dinitrile;
enamine;
substituted aniline		antineoplastic agent;
antioxidant;
apoptosis inducer;
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor;
osteogenesis regulator;
vasoconstrictor agent
sphingosine
sphing-4-enine : A sphingenine in which the C=C double bond is located at the 4-position.. sphingenine : A 2-aminooctadecene-1,3-diol having (2S,3R)-configuration.. sphingoid : Sphinganine, its homologs and stereoisomers, and the hydroxy and unsaturated derivatives of these compounds.. 2-aminooctadec-4-ene-1,3-diol : A 2-aminooctadecene-1,3-diol having its double bond at position 4.		3.1610sphing-4-eninehuman metabolite;
mouse metabolite
bilirubin
[no description available]		2.3110biladienes;
dicarboxylic acid		antioxidant;
human metabolite;
mouse metabolite
fosbretabulin
fosbretabulin: a microtubule destabilizing agent isolated from Combretum caffrum; structure in first source		3.2310
arsenic
Arsenic: A shiny gray element with atomic symbol As, atomic number 33, and atomic weight 75. It occurs throughout the universe, mostly in the form of metallic arsenides. Most forms are toxic. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), arsenic and certain arsenic compounds have been listed as known carcinogens. (From Merck Index, 11th ed)		2.1310metalloid atom;
pnictogen		micronutrient
thermozymocidin
thermozymocidin: a serine palmitoyltransferase inhibitor; FTY720 is an analog		3.1610alpha-amino fatty acid;
hydroxy monocarboxylic acid;
non-proteinogenic alpha-amino acid;
sphingoid		antifungal agent;
antimicrobial agent;
antineoplastic agent;
apoptosis inducer;
EC 2.3.1.50 (serine C-palmitoyltransferase) inhibitor;
fungal metabolite;
immunosuppressive agent
everolimus
[no description available]		3.9521cyclic acetal;
cyclic ketone;
ether;
macrolide lactam;
primary alcohol;
secondary alcohol		anticoronaviral agent;
antineoplastic agent;
geroprotector;
immunosuppressive agent;
mTOR inhibitor
ixabepilone
[no description available]		8.851121,3-thiazoles;
beta-hydroxy ketone;
epoxide;
lactam;
macrocycle		antineoplastic agent;
microtubule-destabilising agent
pep005
3-ingenyl angelate: protein kinase C agonist and antineoplastic; structure in first source		3.2310
taxane
taxane: produced by Taxomyces andreanae		10.52208diterpene;
terpenoid fundamental parent
plitidepsin
plitidepsin: a cyclodepsipeptide isolated from Aplidium albicans; has a pyruvoyl-proline residue instead of the lactyl-proline residue found in the linear peptide moiety of didemnin B. plitidepsin : A didemnin that is didemin B in which the hydroxy group of the 1-(2-hydroxypropanoyl)-L-prolinamide moiety has been oxidised to the corresponding ketone. It was originally isolated from the Mediterranean tunicate Aplidium albicans.		2.4920didemninanticoronaviral agent;
antineoplastic agent;
marine metabolite
lenvatinib
lenvatinib : A member of the class of quinolines that is the carboxamide of 4-{3-chloro-4-[(cyclopropylcarbamoyl)amino]phenoxy}-7-methoxyquinoline-6-carboxylic acid. A multi-kinase inhibitor and orphan drug used (as its mesylate salt) for the treatment of various types of thyroid cancer that do not respond to radioiodine.		3.811aromatic amide;
aromatic ether;
cyclopropanes;
monocarboxylic acid amide;
monochlorobenzenes;
phenylureas;
quinolines		antineoplastic agent;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor;
fibroblast growth factor receptor antagonist;
orphan drug;
vascular endothelial growth factor receptor antagonist
zibotentan
ZD4054: a potent endothelin receptor A antagonist that inhibits ovarian carcinoma cell proliferation		2.0510phenylpyridine
rucaparib
AG14447: Poly(ADP-ribose) polymerase inhibitor; structure in first source		2.1710azepinoindole;
caprolactams;
organofluorine compound;
secondary amino compound		antineoplastic agent;
EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor
halichondrin b
halichondrin B: from marine sponge Halichondria okadai; binds in the Vinca domain of tubulin		13.14307furopyran
pazopanib
pazopanib: a protein kinase inhibitor. pazopanib : A pyrimidine that is 5-(pyrimidin-2-yl}amino-2-methylbenzenesulfonamide substituted at position 4 by a (2,3-dimethylindazol-6-yl)(methyl)amino group. Used as its hydrochloride salt for treatment of kidney cancer.		5.5270aminopyrimidine;
indazoles;
sulfonamide		angiogenesis modulating agent;
antineoplastic agent;
tyrosine kinase inhibitor;
vascular endothelial growth factor receptor antagonist
vinflunine
vinflunine: inhibits tubulin assembly; structure in first source. vinflunine : An organic heteropentacyclic compound and an organic heterotetracyclic compound that is vinorelbine in which the tetrahydropyridine moiety of the heterotetracyclic part of the molecule has been redced to the corresponding piperidine, and in which the ethyl group attached to this ring has been replaced by a 1,1-difluoroethyl group.		3.1410acetate ester;
methyl ester;
organic heteropentacyclic compound;
organic heterotetracyclic compound;
semisynthetic derivative;
vinca alkaloid		antineoplastic agent
epoxomicin
[no description available]		3.2310morpholines;
tripeptide		proteasome inhibitor
bi 2536
[no description available]		2.1110
carfilzomib
[no description available]		3.2310epoxide;
morpholines;
tetrapeptide		antineoplastic agent;
proteasome inhibitor
discodermolide
discodermolide: a lactone-bearing polyhydroxylated alkatetraene from the marine sponge Discodermia dissoluta; microtubule-stabilizing agent like taxol		2.0210
cytochrome c-t
Cytochromes c: Cytochromes of the c type that are found in eukaryotic MITOCHONDRIA. They serve as redox intermediates that accept electrons from MITOCHONDRIAL ELECTRON TRANSPORT COMPLEX III and transfer them to MITOCHONDRIAL ELECTRON TRANSPORT COMPLEX IV.		2.9310
ro5126766
RO5126766: a dual MEK/RAF kinase inhibitor. CH5126766 : A member of the class of coumarins that is 4-methyl-7-[(pyrimidin-2-yl)oxy]coumarin carrying an additional [2-[(methylaminosulfonyl)amino]-3-fluoropyridin-4-yl]methyl substituent at position 3.		2.3110aryloxypyrimidine;
coumarins;
organofluorine compound;
pyridines;
sulfamides		antineoplastic agent;
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor
olaparib
[no description available]		5.4443cyclopropanes;
monofluorobenzenes;
N-acylpiperazine;
phthalazines		antineoplastic agent;
apoptosis inducer;
EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor
mln 8237
MLN 8237: an aurora kinase A inhibitor		2.1310benzazepine
niraparib
niraparib: structure in first source. niraparib : A 2-[4-(piperidin-3-yl)phenyl]-2H-indazole-7-carboxamide that has S-configuration. It is a potent inhibitor of PARP1 and PARP2 (IC50 of 3.8 and 2.1 nM, respectively) and approved as a first-line maintenance treatment for women with advanced ovarian cancer after responding to platinum-based chemotherapy.		2.17102-[4-(piperidin-3-yl)phenyl]-2H-indazole-7-carboxamideantineoplastic agent;
apoptosis inducer;
EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor;
radiosensitizing agent
mk 2206
MK 2206: a protein kinase inhibitor and antineoplastic agent		2.2110organic heterotricyclic compoundEC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor
piperidines
Piperidines: A family of hexahydropyridines.		2.5820
bryostatin 1
bryostatin 1: a protein kinase C activator; macrocyclic lactone from marine Bryozoan Bugula neritina; RN given refers to (1S*-(1R*,3R*,5Z,7S*,8E,11R*,12R*(2E,4E),13E,15R*,17S*(S*),21S*,23S*,25R*))-isomer; structure given in first source; activates protein kinase c. bryostatin 1 : A member of the class of bryostatins that is (17E)-2-oxooxacyclohexacos-17-ene which is substituted by hydroxy groups at positions 4, 10, and 20; an acetoxy group at position 8; methyl groups at positions 9, 9, 18, and 19; 2-methoxy-2-oxoethylidene groups at positions 14 and 24; an (E,E)-octa-2,4-dienoyloxy group at position 21; and with oxygen bridges linking positions 6 to 10, 12 to 16, and 20 to 24. It is one of the most abundant member of the class of bryostatins.		2.0210
apatinib
apatinib: reverses multidrug resistance by inhibiting the efflux function of multiple ATP-binding cassette transporters; structure in first source		4.7211
ascorbic acid
Ascorbic Acid: A six carbon compound related to glucose. It is found naturally in citrus fruits and many vegetables. Ascorbic acid is an essential nutrient in human diets, and necessary to maintain connective tissue and bone. Its biologically active form, vitamin C, functions as a reducing agent and coenzyme in several metabolic pathways. Vitamin C is considered an antioxidant.. L-ascorbic acid : The L-enantiomer of ascorbic acid and conjugate acid of L-ascorbate.. L-ascorbate : The L-enantiomer of ascorbate and conjugate base of L-ascorbic acid, arising from selective deprotonation of the 3-hydroxy group. Required for a range of essential metabolic reactions in all animals and plants.. vitamin C : Any member of a group of vitamers that belong to the chemical structural class called butenolides that exhibit biological activity against vitamin C deficiency in animals. The vitamers include L-ascorbic acid and its salt, ionized and oxidized forms.		2.2110ascorbic acid;
vitamin C		coenzyme;
cofactor;
flour treatment agent;
food antioxidant;
food colour retention agent;
geroprotector;
plant metabolite;
skin lightening agent
warfarin
Warfarin: An anticoagulant that acts by inhibiting the synthesis of vitamin K-dependent coagulation factors. Warfarin is indicated for the prophylaxis and/or treatment of venous thrombosis and its extension, pulmonary embolism, and atrial fibrillation with embolization. It is also used as an adjunct in the prophylaxis of systemic embolism after myocardial infarction. Warfarin is also used as a rodenticide.. warfarin : A racemate comprising equal amounts of (R)- and (S)-warfarin. Extensively used as both an anticoagulant drug and as a pesticide against rats and mice.. 4-hydroxy-3-(3-oxo-1-phenylbutyl)-1-benzopyran-2-one : A member of the class of coumarins that is 4-hydroxycoumarin which is substituted at position 3 by a 1-phenyl-3-oxo-1-butyl group.		2.5120benzenes;
hydroxycoumarin;
methyl ketone
s 1 (combination)
S 1 (combination): consists of tegafur, 5-chloro-2,4-dihydroxyuridine & potassium oxonate; an inhibitor of fluorouracil(5-FU) degradation; prolongs the blood 5-FU level as well as increases selective toxicity to tumor; used for the treatment of colon cancer		3.511
transforming growth factor beta
Transforming Growth Factor beta: A factor synthesized in a wide variety of tissues. It acts synergistically with TGF-alpha in inducing phenotypic transformation and can also act as a negative autocrine growth factor. TGF-beta has a potential role in embryonal development, cellular differentiation, hormone secretion, and immune function. TGF-beta is found mostly as homodimer forms of separate gene products TGF-beta1, TGF-beta2 or TGF-beta3. Heterodimers composed of TGF-beta1 and 2 (TGF-beta1.2) or of TGF-beta2 and 3 (TGF-beta2.3) have been isolated. The TGF-beta proteins are synthesized as precursor proteins.		4.5741
etirinotecan pegol
[no description available]		4.4511
selinexor
selinexor: inhibits karyopherin XPO1		4.0421
guanine
[no description available]		4.96212-aminopurines;
oxopurine;
purine nucleobase		algal metabolite;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
rifampin
Rifampin: A semisynthetic antibiotic produced from Streptomyces mediterranei. It has a broad antibacterial spectrum, including activity against several forms of Mycobacterium. In susceptible organisms it inhibits DNA-dependent RNA polymerase activity by forming a stable complex with the enzyme. It thus suppresses the initiation of RNA synthesis. Rifampin is bactericidal, and acts on both intracellular and extracellular organisms. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p1160)		2.0810cyclic ketal;
hydrazone;
N-iminopiperazine;
N-methylpiperazine;
rifamycins;
semisynthetic derivative;
zwitterion		angiogenesis inhibitor;
antiamoebic agent;
antineoplastic agent;
antitubercular agent;
DNA synthesis inhibitor;
EC 2.7.7.6 (RNA polymerase) inhibitor;
Escherichia coli metabolite;
geroprotector;
leprostatic drug;
neuroprotective agent;
pregnane X receptor agonist;
protein synthesis inhibitor
dacarbazine
(E)-dacarbazine : A dacarbazine in which the N=N double bond adopts a trans-configuration.		8.263dacarbazine
pemetrexed
pemetrexed disodium : An organic sodium salt that is the disodium salt of N-{4-[2-(2-amino-4-oxo-4,7-dihydro-1H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl}-L-glutamic acid. Inhibits thymidylate synthase (TS), 421 dihydrofolate reductase (DHFR), and glycinamide ribonucleotide formyltransferase (GARFT).		4.9621N-acyl-L-glutamic acid;
pyrrolopyrimidine		antimetabolite;
antineoplastic agent;
EC 1.5.1.3 (dihydrofolate reductase) inhibitor;
EC 2.1.1.45 (thymidylate synthase) inhibitor;
EC 2.1.2.2 (phosphoribosylglycinamide formyltransferase) inhibitor
sildenafil citrate
Sildenafil Citrate: A PHOSPHODIESTERASE TYPE-5 INHIBITOR; VASODILATOR AGENT and UROLOGICAL AGENT that is used in the treatment of ERECTILE DYSFUNCTION and PRIMARY PULMONARY HYPERTENSION.. sildenafil citrate : The citrate salt of sildenafil.		2.1710citrate saltEC 3.1.4.35 (3',5'-cyclic-GMP phosphodiesterase) inhibitor;
vasodilator agent
bmn 673
talazoparib: inhibits both PARP1 and PARP2; structure in first source		3.711
ConditionIndicatedRelationship StrengthStudiesTrials
Benign Neoplasms, Brain
[description not available]		07.02111
Disease Models, Animal
Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.		04.5980
Brain Neoplasms
Neoplasms of the intracranial components of the central nervous system, including the cerebral hemispheres, basal ganglia, hypothalamus, thalamus, brain stem, and cerebellum. Brain neoplasms are subdivided into primary (originating from brain tissue) and secondary (i.e., metastatic) forms. Primary neoplasms are subdivided into benign and malignant forms. In general, brain tumors may also be classified by age of onset, histologic type, or presenting location in the brain.		07.02111
Cancer of Lung
[description not available]		011.6269
Lung Neoplasms
Tumors or cancer of the LUNG.		011.6269
Sarcoma, Epithelioid
[description not available]		014.544312
Tumour Lysis Syndrome
[description not available]		02.6320
Sarcoma
A connective tissue neoplasm formed by proliferation of mesodermal cells; it is usually highly malignant.		116.544312
Soft Tissue Neoplasms
Neoplasms of whatever cell type or origin, occurring in the extraskeletal connective tissue framework of the body including the organs of locomotion and their various component structures, such as nerves, blood vessels, lymphatics, etc.		013.462914
Tumor Lysis Syndrome
A syndrome resulting from cytotoxic therapy, occurring generally in aggressive, rapidly proliferating lymphoproliferative disorders. It is characterized by combinations of hyperuricemia, lactic acidosis, hyperkalemia, hyperphosphatemia and hypocalcemia.		02.6320
Breast Cancer
[description not available]		023.13415178
Metastase
[description not available]		020.48186108
Breast Neoplasms
Tumors or cancer of the human BREAST.		127.88830356
Neoplasm Metastasis
The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.		020.48186108
Local Neoplasm Recurrence
[description not available]		013.434623
Lymph Node Metastasis
[description not available]		06.6292
Peripheral Nerve Diseases
[description not available]		012.17247
Peripheral Nervous System Diseases
Diseases of the peripheral nerves external to the brain and spinal cord, which includes diseases of the nerve roots, ganglia, plexi, autonomic nerves, sensory nerves, and motor nerves.		012.17247
Benign Meningeal Neoplasms
[description not available]		02.6320
Angioblastic Meningioma
[description not available]		02.4110
Meningeal Neoplasms
Benign and malignant neoplastic processes that arise from or secondarily involve the meningeal coverings of the brain and spinal cord.		02.6320
Meningioma
A relatively common neoplasm of the CENTRAL NERVOUS SYSTEM that arises from arachnoidal cells. The majority are well differentiated vascular tumors which grow slowly and have a low potential to be invasive, although malignant subtypes occur. Meningiomas have a predilection to arise from the parasagittal region, cerebral convexity, sphenoidal ridge, olfactory groove, and SPINAL CANAL. (From DeVita et al., Cancer: Principles and Practice of Oncology, 5th ed, pp2056-7)		02.4110
ER-Negative PR-Negative HER2-Negative Breast Cancer
[description not available]		013.124212
Triple Negative Breast Neoplasms
Breast neoplasms that do not express ESTROGEN RECEPTORS; PROGESTERONE RECEPTORS; and do not overexpress the NEU RECEPTOR/HER-2 PROTO-ONCOGENE PROTEIN.		115.124212
2019 Novel Coronavirus Disease
[description not available]		02.610
Neutropenia
A decrease in the number of NEUTROPHILS found in the blood.		013.443116
Benign Neoplasms
[description not available]		015.013917
Neoplasms
New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.		119.717834
Febrile Neutropenia
Fever accompanied by a significant reduction in the number of NEUTROPHILS.		05.4622
Atypical Lipomatous Tumor
[description not available]		012.21287
Liposarcoma
A malignant tumor derived from primitive or embryonal lipoblastic cells. It may be composed of well-differentiated fat cells or may be dedifferentiated: myxoid (LIPOSARCOMA, MYXOID), round-celled, or pleomorphic, usually in association with a rich network of capillaries. Recurrences are common and dedifferentiated liposarcomas metastasize to the lungs or serosal surfaces. (From Dorland, 27th ed; Stedman, 25th ed)		012.21287
Leiomyosarcoma, Epithelioid
[description not available]		012.93017
Leiomyosarcoma
A sarcoma containing large spindle cells of smooth muscle. Although it rarely occurs in soft tissue, it is common in the viscera. It is the most common soft tissue sarcoma of the gastrointestinal tract and uterus. The median age of patients is 60 years. (From Dorland, 27th ed; Holland et al., Cancer Medicine, 3d ed, p1865)		012.93017
Adverse Drug Event
[description not available]		05.1631
Drug-Related Side Effects and Adverse Reactions
Disorders that result from the intended use of PHARMACEUTICAL PREPARATIONS. Included in this heading are a broad variety of chemically-induced adverse conditions due to toxicity, DRUG INTERACTIONS, and metabolic effects of pharmaceuticals.		05.1631
Carcinoma, Small Cell Lung
[description not available]		02.6920
Adenocystic Carcinoma
[description not available]		02.920
Cancer of Esophagus
[description not available]		02.610
Cancer of Stomach
[description not available]		04.421
Carcinoma, Adenoid Cystic
Carcinoma characterized by bands or cylinders of hyalinized or mucinous stroma separating or surrounded by nests or cords of small epithelial cells. When the cylinders occur within masses of epithelial cells, they give the tissue a perforated, sievelike, or cribriform appearance. Such tumors occur in the mammary glands, the mucous glands of the upper and lower respiratory tract, and the salivary glands. They are malignant but slow-growing, and tend to spread locally via the nerves. (Dorland, 27th ed)		02.920
Esophageal Neoplasms
Tumors or cancer of the ESOPHAGUS.		02.610
Stomach Neoplasms
Tumors or cancer of the STOMACH.		04.421
Small Cell Lung Carcinoma
A form of highly malignant lung cancer that is composed of small ovoid cells (SMALL CELL CARCINOMA).		02.6920
Acute-On-Chronic Liver Failure (ACLF)
[description not available]		02.4110
Cancer of Liver
[description not available]		07.42132
Liver Neoplasms
Tumors or cancer of the LIVER.		07.42132
Acute-On-Chronic Liver Failure
Sudden liver failure in the presence of underlying compensated chronic LIVER DISEASE (e.g., LIVER CIRRHOSIS; HEPATITIS; and liver injury and failure) due to a precipitating acute hepatic insult.		02.4110
Colorectal Cancer
[description not available]		02.6620
Colorectal Neoplasms
Tumors or cancer of the COLON or the RECTUM or both. Risk factors for colorectal cancer include chronic ULCERATIVE COLITIS; FAMILIAL POLYPOSIS COLI; exposure to ASBESTOS; and irradiation of the CERVIX UTERI.		02.6620
Carcinoma, Anaplastic
[description not available]		06.7673
Cell Transformation, Neoplastic
Cell changes manifested by escape from control mechanisms, increased growth potential, alterations in the cell surface, karyotypic abnormalities, morphological and biochemical deviations from the norm, and other attributes conferring the ability to invade, metastasize, and kill.		02.6120
Cancer of Ovary
[description not available]		08.91106
Carcinoma
A malignant neoplasm made up of epithelial cells tending to infiltrate the surrounding tissues and give rise to metastases. It is a histological type of neoplasm and not a synonym for cancer.		06.7673
Carcinosarcoma
A malignant neoplasm that contains elements of carcinoma and sarcoma so extensively intermixed as to indicate neoplasia of epithelial and mesenchymal tissue. (Stedman, 25th ed)		02.4110
Ovarian Neoplasms
Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS.		110.91106
Cancer of Pancreas
[description not available]		06191
Pancreatic Neoplasms
Tumors or cancer of the PANCREAS. Depending on the types of ISLET CELLS present in the tumors, various hormones can be secreted: GLUCAGON from PANCREATIC ALPHA CELLS; INSULIN from PANCREATIC BETA CELLS; and SOMATOSTATIN from the SOMATOSTATIN-SECRETING CELLS. Most are malignant except the insulin-producing tumors (INSULINOMA).		06191
Pulmonary Arterial Remodeling
[description not available]		04.4970
Anoxemia
[description not available]		02.610
Hypoxia
Sub-optimal OXYGEN levels in the ambient air of living organisms.		02.610
Angiosarcoma
[description not available]		03.7280
Cancer of Skin
[description not available]		03.87100
Hemangiosarcoma
A rare malignant neoplasm characterized by rapidly proliferating, extensively infiltrating, anaplastic cells derived from blood vessels and lining irregular blood-filled or lumpy spaces. (Stedman, 25th ed)		15.7280
Skin Neoplasms
Tumors or cancer of the SKIN.		03.87100
Cancer of Cervix
[description not available]		03.9911
Uterine Cervical Neoplasms
Tumors or cancer of the UTERINE CERVIX.		03.9911
Desmoplastic Small Cell Tumor
[description not available]		02.6620
Desmoplastic Small Round Cell Tumor
A rare, aggressive soft tissue sarcoma that primarily affects adolescents and young adults. It is most commonly found in the abdomen.		02.6620
Carcinoma, Epidermoid
[description not available]		05.9383
Carcinoma, Squamous Cell
A carcinoma derived from stratified SQUAMOUS EPITHELIAL CELLS. It may also occur in sites where glandular or columnar epithelium is normally present. (From Stedman, 25th ed)		05.9383
Dermatitis, Radiation-Induced
[description not available]		02.610
Radiodermatitis
A cutaneous inflammatory reaction occurring as a result of exposure to ionizing radiation.		02.610
Carcinogenesis
The origin, production or development of cancer through genotypic and phenotypic changes which upset the normal balance between cell proliferation and cell death. Carcinogenesis generally requires a constellation of steps, which may occur quickly or over a period of many years.		02.6620
Osteogenic Sarcoma
[description not available]		05.8871
Osteosarcoma
A sarcoma originating in bone-forming cells, affecting the ends of long bones. It is the most common and most malignant of sarcomas of the bones, and occurs chiefly among 10- to 25-year-old youths. (From Stedman, 25th ed)		05.8871
Cells, Neoplasm Circulating
[description not available]		04.8332
Diffuse Parenchymal Lung Disease
[description not available]		02.5920
Allergic Alveolitis, Extrinsic
[description not available]		02.2510
Alveolitis, Extrinsic Allergic
A common interstitial lung disease caused by hypersensitivity reactions of PULMONARY ALVEOLI after inhalation of and sensitization to environmental antigens of microbial, animal, or chemical sources. The disease is characterized by lymphocytic alveolitis and granulomatous pneumonitis.		02.2510
Lung Diseases, Interstitial
A diverse group of lung diseases that affect the lung parenchyma. They are characterized by an initial inflammation of PULMONARY ALVEOLI that extends to the interstitium and beyond leading to diffuse PULMONARY FIBROSIS. Interstitial lung diseases are classified by their etiology (known or unknown causes), and radiological-pathological features.		02.5920
Encephalopathy, Toxic
[description not available]		03.1210
Cardiac Cancer
[description not available]		02.6120
Rhabdomyosarcoma
A malignant solid tumor arising from mesenchymal tissues which normally differentiate to form striated muscle. It can occur in a wide variety of sites. It is divided into four distinct types: pleomorphic, predominantly in male adults; alveolar (RHABDOMYOSARCOMA, ALVEOLAR), mainly in adolescents and young adults; embryonal (RHABDOMYOSARCOMA, EMBRYONAL), predominantly in infants and children; and botryoidal, also in young children. It is one of the most frequently occurring soft tissue sarcomas and the most common in children under 15. (From Dorland, 27th ed; Holland et al., Cancer Medicine, 3d ed, p2186; DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, pp1647-9)		03.0840
Clear Cell Sarcoma of Soft Tissue
[description not available]		02.2510
Sarcoma, Clear Cell
A sarcoma of young adults occurring in the lower extremities and acral regions. It is found intimately bound to tendons as a circumscribed but unencapsulated melanin-bearing tumor of neuroectodermal origin. Clear cell sarcoma is associated with a specific t(12;22)(q13;q12) translocation.		02.2510
Chronic Kidney Diseases
[description not available]		02.2510
Renal Insufficiency, Chronic
Conditions in which the KIDNEYS perform below the normal level for more than three months. Chronic kidney insufficiency is classified by five stages according to the decline in GLOMERULAR FILTRATION RATE and the degree of kidney damage (as measured by the level of PROTEINURIA). The most severe form is the end-stage renal disease (CHRONIC KIDNEY FAILURE). (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002)		02.2510
Disease Exacerbation
[description not available]		09.35212
Single Functioning Kidney
[description not available]		02.2510
Retroperitoneal Neoplasms
New abnormal growth of tissue in the RETROPERITONEAL SPACE.		02.5920
Male Genital Neoplasms
[description not available]		02.2510
Genital Neoplasms, Male
Tumor or cancer of the MALE GENITALIA.		02.2510
Acute Lymphoid Leukemia
[description not available]		02.2510
Precursor Cell Lymphoblastic Leukemia-Lymphoma
A neoplasm characterized by abnormalities of the lymphoid cell precursors leading to excessive lymphoblasts in the marrow and other organs. It is the most common cancer in children and accounts for the vast majority of all childhood leukemias.		02.2510
Cancer of Kidney
[description not available]		02.5920
Bilateral Wilms Tumor
[description not available]		02.2510
Kidney Neoplasms
Tumors or cancers of the KIDNEY.		02.5920
Wilms Tumor
A malignant kidney tumor, caused by the uncontrolled multiplication of renal stem (blastemal), stromal (STROMAL CELLS), and epithelial (EPITHELIAL CELLS) elements. However, not all three are present in every case. Several genes or chromosomal areas have been associated with Wilms tumor which is usually found in childhood as a firm lump in a child's side or ABDOMEN.		02.2510
Cholera Infantum
[description not available]		05.4322
Blood Diseases
[description not available]		05.4322
Hematologic Diseases
Disorders of the blood and blood forming tissues.		05.4322
Ductal Carcinoma
[description not available]		02.2510
Carcinoma, Ductal
Malignant neoplasms involving the ductal systems of any of a number of organs, such as the MAMMARY GLANDS, the PANCREAS, the PROSTATE, or the LACRIMAL GLAND.		02.2510
Bone Cancer
[description not available]		09.22143
Bone Neoplasms
Tumors or cancer located in bone tissue or specific BONES.		09.22143
Innate Inflammatory Response
[description not available]		04.0421
Inflammation
A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.		04.0421
Hormone-Dependent Neoplasms
[description not available]		04.0421
Carcinoma, Squamous Cell of Head and Neck
[description not available]		02.3110
Cancer of Mouth
[description not available]		03.2850
Squamous Cell Carcinoma of Head and Neck
The most common type of head and neck carcinoma that originates from cells on the surface of the NASAL CAVITY; MOUTH; PARANASAL SINUSES, SALIVARY GLANDS, and LARYNX. Mutations in TNFRSF10B, PTEN, and ING1 genes are associated with this cancer.		02.3110
Mouth Neoplasms
Tumors or cancer of the MOUTH.		03.2850
Fibrillary Chorea
[description not available]		02.5920
Necrosis
The death of cells in an organ or tissue due to disease, injury or failure of the blood supply.		02.3110
Cancer of Salivary Gland
[description not available]		04.0221
Salivary Gland Neoplasms
Tumors or cancer of the SALIVARY GLANDS.		04.0221
Kaposi Sarcoma
[description not available]		02.3110
Sarcoma, Kaposi
A multicentric, malignant neoplastic vascular proliferation characterized by the development of bluish-red cutaneous nodules, usually on the lower extremities, most often on the toes or feet, and slowly increasing in size and number and spreading to more proximal areas. The tumors have endothelium-lined channels and vascular spaces admixed with variably sized aggregates of spindle-shaped cells, and often remain confined to the skin and subcutaneous tissue, but widespread visceral involvement may occur. Kaposi's sarcoma occurs spontaneously in Jewish and Italian males in Europe and the United States. An aggressive variant in young children is endemic in some areas of Africa. A third form occurs in about 0.04% of kidney transplant patients. There is also a high incidence in AIDS patients. (From Dorland, 27th ed & Holland et al., Cancer Medicine, 3d ed, pp2105-7) HHV-8 is the suspected cause.		02.3110
Intussusception
A form of intestinal obstruction caused by the PROLAPSE of a part of the intestine into the adjoining intestinal lumen. There are four types: colic, involving segments of the LARGE INTESTINE; enteric, involving only the SMALL INTESTINE; ileocecal, in which the ILEOCECAL VALVE prolapses into the CECUM, drawing the ILEUM along with it; and ileocolic, in which the ileum prolapses through the ileocecal valve into the COLON.		02.3110
Angiogenesis, Pathologic
[description not available]		05.1730
Anal Gland Neoplasms
Tumors or cancer of the anal gland.		02.4110
Invasiveness, Neoplasm
[description not available]		04.2631
Fibrosarcoma
A sarcoma derived from deep fibrous tissue, characterized by bundles of immature proliferating fibroblasts with variable collagen formation, which tends to invade locally and metastasize by the bloodstream. (Stedman, 25th ed)		02.3110
Cancer-Associated Pain
[description not available]		04.4511
Breathlessness
[description not available]		04.4511
Lassitude
[description not available]		08.8974
Chronic Insomnia
[description not available]		04.4511
Emesis
[description not available]		04.4511
Cancer Pain
Pain that may be caused by or related to cellular, tissue, and systemic changes that occur during NEOPLASM growth, tissue invasion, and METASTASIS.		04.4511
Anorexia
The lack or loss of APPETITE accompanied by an aversion to food and the inability to eat. It is the defining characteristic of the disorder ANOREXIA NERVOSA.		06.7733
Dyspnea
Difficult or labored breathing.		04.4511
Fatigue
The state of weariness following a period of exertion, mental or physical, characterized by a decreased capacity for work and reduced efficiency to respond to stimuli.		08.8974
Sleep Initiation and Maintenance Disorders
Disorders characterized by impairment of the ability to initiate or maintain sleep. This may occur as a primary disorder or in association with another medical or psychiatric condition.		04.4511
Nausea
An unpleasant sensation in the stomach usually accompanied by the urge to vomit. Common causes are early pregnancy, sea and motion sickness, emotional stress, intense pain, food poisoning, and various enteroviruses.		06.9843
Vomiting
The forcible expulsion of the contents of the STOMACH through the MOUTH.		04.4511
Lesion of Sciatic Nerve
[description not available]		02.8430
Cancer, Second Primary
[description not available]		02.1510
Malignant Melanoma
[description not available]		04.2231
Melanoma
A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445)		17.3462
Body Weight
The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.		02.5120
Ewing Sarcoma
[description not available]		02.1710
Sarcoma, Ewing
A malignant tumor of the bone which always arises in the medullary tissue, occurring more often in cylindrical bones. The tumor occurs usually before the age of 20, about twice as frequently in males as in females.		02.1710
Peritoneal Carcinomatosis
[description not available]		02.1510
Peritoneal Neoplasms
Tumors or cancer of the PERITONEUM.		02.1510
Carcinoma, Non-Small Cell Lung
[description not available]		09.396
Carcinoma, Non-Small-Cell Lung
A heterogeneous aggregate of at least three distinct histological types of lung cancer, including SQUAMOUS CELL CARCINOMA; ADENOCARCINOMA; and LARGE CELL CARCINOMA. They are dealt with collectively because of their shared treatment strategy.		111.396
Experimental Lung Inflammation
Inflammation of any part, segment or lobe, of the lung parenchyma.		04.4811
Chemotherapy-Induced Febrile Neutropenia
FEVER accompanied by a significant reduction in NEUTROPHIL count associated with CHEMOTHERAPY.		04.4811
Pneumonia
Infection of the lung often accompanied by inflammation.		04.4811
Carcinoma, Ductal, Breast
An invasive (infiltrating) CARCINOMA of the mammary ductal system (MAMMARY GLANDS) in the human BREAST.		06.7671
Breast Cancer, Male
[description not available]		02.1710
Breast Neoplasms, Male
Any neoplasms of the male breast. These occur infrequently in males in developed countries, the incidence being about 1% of that in females.		02.1710
Cancer of Head
[description not available]		04.231
Head and Neck Neoplasms
Soft tissue tumors or cancer arising from the mucosal surfaces of the LIP; oral cavity; PHARYNX; LARYNX; and cervical esophagus. Other sites included are the NOSE and PARANASAL SINUSES; SALIVARY GLANDS; THYROID GLAND and PARATHYROID GLANDS; and MELANOMA and non-melanoma skin cancers of the head and neck. (from Holland et al., Cancer Medicine, 4th ed, p1651)		04.231
Astrocytoma, Grade IV
[description not available]		02.5920
Glioblastoma
A malignant form of astrocytoma histologically characterized by pleomorphism of cells, nuclear atypia, microhemorrhage, and necrosis. They may arise in any region of the central nervous system, with a predilection for the cerebral hemispheres, basal ganglia, and commissural pathways. Clinical presentation most frequently occurs in the fifth or sixth decade of life with focal neurologic signs or seizures.		02.5920
Recrudescence
[description not available]		09.45105
Carcinoma, Lobular
A type of BREAST CANCER where the abnormal malignant cells form in the lobules, or milk-producing glands, of the breast.		06.0731
Myxoid Liposarcoma
[description not available]		03.0910
Liposarcoma, Myxoid
A liposarcoma containing round mesenchymal cells and a myxoid extracellular matrix in stroma.		03.0910
Acute Kidney Failure
[description not available]		02.1710
Cancer of the Uterus
[description not available]		02.5220
Uterine Neoplasms
Tumors or cancer of the UTERUS.		02.5220
Acute Kidney Injury
Abrupt reduction in kidney function. Acute kidney injury encompasses the entire spectrum of the syndrome including acute kidney failure; ACUTE KIDNEY TUBULAR NECROSIS; and other less severe conditions.		02.1710
Cancer of Prostate
[description not available]		05.8442
Prostatic Neoplasms
Tumors or cancer of the PROSTATE.		05.8442
Pneumothorax, Primary Spontaneous
[description not available]		02.2110
Pneumothorax
An accumulation of air or gas in the PLEURAL CAVITY, which may occur spontaneously or as a result of trauma or a pathological process. The gas may also be introduced deliberately during PNEUMOTHORAX, ARTIFICIAL.		02.2110
Experimental Neoplasms
[description not available]		02.4820
Neoplasms, Bone Marrow
[description not available]		02.0810
Bone Marrow Neoplasms
Neoplasms located in the bone marrow. They are differentiated from neoplasms composed of bone marrow cells, such as MULTIPLE MYELOMA. Most bone marrow neoplasms are metastatic.		02.0810
Carcinomatous Meningitis
[description not available]		02.110
Meningeal Carcinomatosis
Primary or secondary neoplasm in the ARACHNOID or SUBARACHNOID SPACE. It appears as a diffuse fibrotic thickening of the MENINGES associated with variable degrees of inflammation.		02.110
Aging
The gradual irreversible changes in structure and function of an organism that occur as a result of the passage of time.		09.7199
Alopecia Cicatrisata
[description not available]		07.2342
Alopecia
Absence of hair from areas where it is normally present.		07.2342
Anemia, Hemolytic, Acquired
[description not available]		02.110
Anemia, Hemolytic
A condition of inadequate circulating red blood cells (ANEMIA) or insufficient HEMOGLOBIN due to premature destruction of red blood cells (ERYTHROCYTES).		02.110
Infection
[description not available]		02.1110
Infections
Invasion of the host organism by microorganisms or their toxins or by parasites that can cause pathological conditions or diseases.		02.1110
Adenocarcinoma, Scirrhous
An adenocarcinoma with a hard (Greek skirrhos, hard) structure owing to the formation of dense connective tissue in the stroma. (From Dorland, 27th ed)		02.110
Adenocarcinoma, Basal Cell
[description not available]		04.7232
Cancer of Intestines
[description not available]		02.1110
Adenocarcinoma
A malignant epithelial tumor with a glandular organization.		04.7232
Intestinal Neoplasms
Tumors or cancer of the INTESTINES.		02.1110
Cancer of Eye
[description not available]		02.110
Asthenia
Clinical sign or symptom manifested as debility, or lack or loss of strength and energy.		02.1110
Leukocytopenia
[description not available]		03.511
Leukopenia
A decrease in the number of LEUKOCYTES in a blood sample below the normal range (LEUKOCYTE COUNT less than 4000).		03.511
Cancer of the Retina
[description not available]		02.1110
Clinically Isolated CNS Demyelinating Syndrome
[description not available]		02.1310
Polyneuropathy, Acquired
[description not available]		02.4920
Demyelinating Diseases
Diseases characterized by loss or dysfunction of myelin in the central or peripheral nervous system.		02.1310
Polyneuropathies
Diseases of multiple peripheral nerves simultaneously. Polyneuropathies usually are characterized by symmetrical, bilateral distal motor and sensory impairment with a graded increase in severity distally. The pathological processes affecting peripheral nerves include degeneration of the axon, myelin or both. The various forms of polyneuropathy are categorized by the type of nerve affected (e.g., sensory, motor, or autonomic), by the distribution of nerve injury (e.g., distal vs. proximal), by nerve component primarily affected (e.g., demyelinating vs. axonal), by etiology, or by pattern of inheritance.		02.4920
Lymphocytopenia
[description not available]		03.511
Cancer of the Urinary Tract
[description not available]		03.511
Lymphopenia
Reduction in the number of lymphocytes.		03.511
Kidney Diseases
Pathological processes of the KIDNEY or its component tissues.		04.4111
Cancer of Endometrium
[description not available]		04.4111
Endometrial Neoplasms
Tumors or cancer of ENDOMETRIUM, the mucous lining of the UTERUS. These neoplasms can be benign or malignant. Their classification and grading are based on the various cell types and the percent of undifferentiated cells.		04.4111
Response Evaluation Criteria in Solid Tumors
An internationally recognized set of published rules used for evaluation of cancer treatment that define when tumors found in cancer patients improve, worsen, or remain stable during treatment. These criteria are based specifically on the response of the tumor(s) to treatment, and not on the overall health status of the patient resulting from treatment.		04.8421
Acute Liver Injury, Drug-Induced
[description not available]		02.1310
Liver Dysfunction
[description not available]		02.1310
Liver Diseases
Pathological processes of the LIVER.		02.1310
Chemical and Drug Induced Liver Injury
A spectrum of clinical liver diseases ranging from mild biochemical abnormalities to ACUTE LIVER FAILURE, caused by drugs, drug metabolites, herbal and dietary supplements and chemicals from the environment.		02.1310
Obesity
A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).		02.1310
Connective and Soft Tissue Neoplasms
[description not available]		04.4511
Benign Cerebellar Neoplasms
[description not available]		02.1510
Neoplasms, Pleural
[description not available]		02.1510
Solitary Fibrous Tumors
Rare neoplasms of mesenchymal origin, usually benign, and most commonly involving the PLEURA (see SOLITARY FIBROUS TUMOR, PLEURAL). They also are found in extrapleural sites.		14.1510
Sensitivity and Specificity
Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed)		02.4620
Carcinoma, Large Cell
A tumor of undifferentiated (anaplastic) cells of large size. It is usually bronchogenic. (From Dorland, 27th ed)		03.4611
Synovioma
[description not available]		09.6899
Sarcoma, Synovial
A malignant neoplasm arising from tenosynovial tissue of the joints and in synovial cells of tendons and bursae. The legs are the most common site, but the tumor can occur in the abdominal wall and other trunk muscles. There are two recognized types: the monophasic (characterized by sheaths of monotonous spindle cells) and the biphasic (characterized by slit-like spaces or clefts within the tumor, lined by cuboidal or tall columnar epithelial cells). These sarcomas occur most commonly in the second and fourth decades of life. (From Dorland, 27th ed; DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p1363)		09.6899
Endolymphatic Stromal Myosis
[description not available]		02.0710
Hepatic Insufficiency
Conditions in which the LIVER functions fall below the normal ranges. Severe hepatic insufficiency may cause LIVER FAILURE or DEATH. Treatment may include LIVER TRANSPLANTATION.		03.4611
Fasting Hypoglycemia
HYPOGLYCEMIA expressed in the postabsorptive state, after prolonged FASTING, or an overnight fast.		02.0310
Hypoglycemia
A syndrome of abnormally low BLOOD GLUCOSE level. Clinical hypoglycemia has diverse etiologies. Severe hypoglycemia eventually lead to glucose deprivation of the CENTRAL NERVOUS SYSTEM resulting in HUNGER; SWEATING; PARESTHESIA; impaired mental function; SEIZURES; COMA; and even DEATH.		02.0310
Hypophosphatemia
A condition of an abnormally low level of PHOSPHATES in the blood.		02.0310